All the below links are in English.
取り急ぎ以下貼っておきます。
World Vol.51
World Vol.50
World Vol.49
World Vol.48
World Vol.47
World Vol.46
World Vol.45
World Vol.44
World Vol.43
World Vol.42
World Vol.41
タグ: 欧州 Europe
U.S.A. アメリカ Vol.123（New Jersey ニュージャージー州 Vol.4: pharmaceutical corporations 製薬会社）
All the below link and tweets are in English.
Vol.122 (New Jersey ニュージャージー州 Vol.3: pharmaceutical corporations 製薬会社）の続き
ツイッター検索で 上記製薬会社名 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの
Japan's PeptiDream to work with Merck in developing COVID-19 therapies https://t.co/GzIqX0LbZQ pic.twitter.com/T8MxO4ZuZu
— Reuters (@Reuters) June 12, 2020
CDC Director Brenda Fitzgerald bought stock in Japan Tobacco, Merck and Humana– *AFTER* she became the nation's top public health official.
The investigation from @SarahKarlin
& @Briannaehley: https://t.co/gHNHqOP8IG— Adam Cancryn (@adamcancryn) January 30, 2018
During COVID, the growing dangers and threat posed by antibiotic-resistant bacteria outweigh the global level of preparedness. Meanwhile, antibiotic R&D is suffering for investment. Forge applauds @Merck and Kyorin for supporting @PewCharitableTrust https://t.co/i0ToNjccgt
— Forge Therapeutics (@ForgeThera) October 23, 2020
New data from Merck, Kyorin shared to Pew's SPARK @pewtrusts @Merckhttps://t.co/ibg9R6JXFn
— The Science Advisory Board (@ScienceBoard) October 21, 2020
“Our hope is that the data from @Merck’s research will help catalyze discovery of new #antibiotics for Gram-negative pathogens,” @pewhealth’s @KathrynTalking says of the pharmaceutical company’s recent data contribution to SPARK. https://t.co/qd6oOf3y15
— Save Antibiotics (@saveantibiotics) October 21, 2020
Japan Prize / Merck-Banyu Lectureship for Naoya Kumagai / DECHEMA Prize for Timothy Noeel (News) https://t.co/npKfaLlQBg pic.twitter.com/6Q1xQyXK11
— Angewandte Chemie (@angew_chem) April 26, 2018
In today's News Briefing: Two years unveiling a flop in their first PhIII trial of guadecitabine as a frontline treatment, Otsuka is back with 2 more pivotal setbacks. And the #FDA approved an expanded indication for Merck’s best-seller Keytruda. https://t.co/5svHdzG7UG
— Endpoints News (@endpts) October 16, 2020
Merck adds to lung cancer wall with Otsuka deal https://t.co/l9RW0Njibg pic.twitter.com/GnYs2TWMeI
— HealthIT and Biotech (@UCCharting) January 9, 2020
Merck adds to lung cancer wall with Otsuka deal | BioPharma Dive https://t.co/k063lZ3W8E
— Mr. Brian Uberig (@Brian_Uberig) January 8, 2020
MSD enlists Otsuka units Taiho and Astex to develop KRAS therapies https://t.co/2QOB4obxMj #pharma #healthcare
— PharmaTimes (@PharmaTimes) January 8, 2020
Merck and Otsuka enter into a research and development pact for a drug that targets a dangerous subset of cancers https://t.co/8ESVh069oT
— Bloomberg (@business) January 7, 2020
Merck & Co. partners with Otsuka units Taiho, Astex on cancer drug development https://t.co/qu7yCDMN5P $MRK $ASTX
— FirstWord Pharma (@fwpharma) January 6, 2020
Industry Insight of Oncolytic Virus Market Research Segment, In-depth Analysis | Merck, Otsuka Pharmaceutical Co, Pfizerhttps://t.co/lnfmzWgTWA#news #pharma #pharmiweb
— Pharma News (@pharminews) December 24, 2019
Oncolytic Virus Market Analysis and Reviews 2019 to 2025 | Merck, Otsuka Pharmaceutical Co, Pfizer, Roche, Cold Genesys, Genelux https://t.co/5MnJLhS6t2 pic.twitter.com/4THnWUqxql
— Science Examiner (@ScienceExaminer) October 7, 2019
Analyst Keshalini Sabaratnam @Pharma_GD on the #sales #forecast for @Merck and #Otsuka 's #Keytruda (pembrolizumab) projected to be top drug by 2023 and what does this mean for their #contractmanufacturers #CDMO #CMO @AstraZeneca @BoehringerDE https://t.co/R6Wmwcm2Qb
— GlobalData PharmSource (@PharmSource) October 2, 2019
The $200 discount for the Marketing Disruption Summit ends Friday! Explore the full agenda and get your tickets here: https://t.co/sueo5mBZEd#sanofi #BMS #ferring #boehringeringelheim #merck #teva #gsk #abbvie #astrazeneca #pfizer #bayer #otsuka #us #pharma #marketing #data #it pic.twitter.com/u9P8j4mLcn
— Reuters Events Pharma (@RE_Pharma) August 14, 2019
Otsuka buying Waltham, Mass.-based antibody specialist Visterra for $430 million, all-cash. https://t.co/FIwi2S4VeB
Last valuation was $188 million, per Pitchbook. Omega, Alexandria, Cycad Group, Gates Foundation, Merck, Vertex, Temasek, Alexandria among investors.
— Matthew Herper (@matthewherper) July 11, 2018
"Editor’s note: The author did not initially disclose having received payments from Boehringer Ingelheim, Eli Lilly, Hoffmann-La Roche, Lundbeck, Merck, Sharpe, and Dohme, Otsuka, Pfizer, and other companies." You have to ask – why the delay? @AmerGeriatrics https://t.co/RWpZYRJ7zK
— James Richardson, MD, MPH (@DocRock54) March 10, 2018
Merck and Otsuka US agree: Misalignment in healthcare is our biggest cha… https://t.co/H2U3iCqVZ1 via @YouTube
— Tim Nolan (@TimNolan1941) August 17, 2017
ESMO: Where will Merck, Eisai take Keytruda-Lenvima next? Ovarian and colorectal cancer could be good options, data show https://t.co/mjqD8dcsru
— cafepharma (@cafepharma) September 20, 2020
Chasing Merck, Eisai launches insomnia drug Dayvigo in Japan https://t.co/e3JM6pAqPX
— cafepharma (@cafepharma) July 7, 2020
https://twitter.com/LRamseu/status/1312391912956010498
Merck, Eisai's Keytruda-Lenvima combo stonewalled in liver cancer after Roche's first-in-class green light #livercancernews https://t.co/uJyJ0rpuoG
— Blue Faery (@BlueFaeryLiver) September 16, 2020
US rejects MSD/Eisai's Keytruda Lenvima combo https://t.co/U6bwJRTYcK #lifesciences #news
— PharmaTimes (@PharmaTimes) July 9, 2020
Merck, Eisai's Keytruda-Lenvima combo stonewalled in liver cancer after Roche's first-in-class green light https://t.co/fCgfHt2mPc
— FiercePharma (@FiercePharma) July 8, 2020
Merck, Eisai to put experimental cancer combination in new clinical trial https://t.co/LuQoPj699g
— MarketWatch (@MarketWatch) July 8, 2020
Merck, Eisai to put experimental cancer combination in new clinical trial https://t.co/uoyKGe8up0
— MMC Anchor (@MMCAnchor) July 8, 2020
ASCO: Merck, Eisai pad case for liver cancer nod with Keytruda-Lenvima combo data https://t.co/f6piWgmPOf
— EIPG (@EIPGeu) June 1, 2020
.@Merck/@Eisai's Keytruda/Lenvima combo 1st to win simultaneous approvals from @US_FDA, @GovCanHealth & @TGAgovau under new international regulatory program for #cancer drugs, writes @biotechvisigoth. $MRK #oncology https://t.co/nAfqQ8mUqL
— MedCity News (@medcitynews) September 18, 2019
New #paediatric treatments recently launched for #HIV #soiltransmittedhelminths #epilepsy and #pneumonia from 4 companies detailed in #atmi2018 today: @GSK @JNJNews @Merck @eisai …. #worldChildrensDay2018 #WorldChildrensDay https://t.co/qnb3DoC0m1
— Danny Edwards (@dannyjedwards) November 20, 2018
#Eisai, #MSD start marketing activity for #LENVIMA https://t.co/qGiJ2CwZx0 via @AsiaBioSpectrum
— Sudam Walekar (@sudam_walekar) October 23, 2018
Eisai and MSD Japan Commence Collaboration on Commercialization Activities for LENVIMA (Lenvatinib) in Japan https://t.co/oLX4MT3Vnu
— EIN Presswire: Merck Newswire (@EINMerckNews) October 22, 2018
Eisai/MSD’s Lenvima approved in Europe for liver cancer https://t.co/pPxoYTKCzG pic.twitter.com/Itatzdg438
— PIR International (@PIR_Intl) August 28, 2018
Merck, Eisai win FDA approval for Lenvima to treat unresectable HCC https://t.co/5tlVxTAiLO
— NGT Consulting (@NextGeneTherapy) August 20, 2018
Eisai and MSD team up to combine Lenvima and Keytruda in cancer https://t.co/K7XtG4RWnv pic.twitter.com/R9fukbkYeX
— Pharmamarketeer (@Pharmamarketeer) March 13, 2018
Merck partners with Eisai's Tyrosine Kinase inhibitor drug Lenvatinib with apotential deal of over 5 billion dollars#merck #Eisai #Checkpointinhibitor #Tyrosinerkinaseinhibitor #combination #billiondollar #deal #treat #malignancieshttps://t.co/NXsLRtc17N
— Neil Sankar (@SankarNeil) March 12, 2018
Merck and Eisai Ink $5.76B Cancer Deal https://t.co/bKH5FnuCC9 pic.twitter.com/RI1iJIIqLI
— Biotech World (@BiotechWorld) March 9, 2018
Eisai and MSD will jointly develop and commercialize a thyroid cancer therapy – https://t.co/Z1TfQSlksY pic.twitter.com/QVLB0ppzJT
— GMPnews.Net (@GMPnewsNet) March 8, 2018
Our final panel session at @PharEast2018 features Representatives from @JNJCares, Eisai Japan, MSD Singapore and Fosub-kite discussing on using real world evidence (RWD) to support the rational use of medicine in Asia. #phareast pic.twitter.com/LD4Y0kmqE4
— Phar-East (@PharEast2018) March 2, 2018
@gatesfoundation , @wellcometrust & @Mastercard Launch Initiative to Speed Development and Access to Therapies for COVID-19#COVID19TherapeuticsAccelerator #Covid19https://t.co/ATA8tRBLc7#BD #BI #Eisai #EliLilly #Gilead #GSK #JandJ #MSD #Merck #Novartis #Pfizer #Sanofi
— Claude Waddington (@Mr_C_Wadd) March 30, 2020
MSD and Eisai announce meaningful objective response rates for Keytruda+Lenvima combo in two cancer patient populations https://t.co/dRtWAbK5fk #pharma pic.twitter.com/2YDFuIMvrs
— Pharmafocus (@Pharmafocus) May 29, 2020
Eisai and MSD's Lenvima recommended for NHS Scotland in advanced or unresectable #LiverCancer https://t.co/bhdX1Yb5qR #cancer #pharma #NHS pic.twitter.com/H2qvj5SrrE
— Pharmafocus (@Pharmafocus) April 8, 2019
Thank you to our No One Fights Alone Virtual Gala Celebration sponsors, including Platinum Ribbon Sponsors, Amgen, Merck, Oncosec Immunotherapies, and Silver Ribbon Sponsors, Eisai and Immunomedics. Your generosity and support make it all possible. https://t.co/B8RsqHB5bW pic.twitter.com/KungeoGTTb
— TNBC Foundation (@TNBCFoundation) October 23, 2020
These pharma fleecers, including Takeda, Eisai, Merck, and Genentech, choose to sell their expensive oncology drugs in excessively large drug vials that lead to waste. They got my second #PharmaFleeceAward today.
— Senator Dick Durbin (@SenatorDurbin) March 14, 2019
Daiichi Sankyo signs clinical trial collaboration deal with Merck and Pfizer: Daiichi Sankyo has entered into a clinical trial collaboration agreement with Merck and Pfizer to evaluate the combination of its [fam-] trastuzumab deruxtecan (DS-8201) with… https://t.co/N83w7zGYxv
— cafepharma (@cafepharma) October 26, 2018
Daiichi-Merck partnership lines up Keytruda combo therapy https://t.co/YnoL7Sa9B6 pic.twitter.com/9Ocwq2ei5F
— JackLeckerman (@JackLeckerman) October 9, 2018
Daiichi Sankyo has entered into a clinical trial collaboration agreement with a subsidiary of MSD to evaluate a potential new combination therapy for breast or lung cancershttps://t.co/i08ieVPnZY pic.twitter.com/F3ZuKh8KUs
— Bio_Talent (@bio_talent) September 28, 2018
Unfortunately message is suspect bc of COI. F. Schiele reports personal fees from Board membership, consultancy, or lecturing from Sanofi, Amgen, Pfizer, AZ, MSD, BMS, Bayer & Daiichi-Sankyo. Steen Dalby Kristensen has recd lecture fees from AZ, Bayer, BMS/Pfizer and Boehringer- https://t.co/mKikYa72D9
— Ram Charan (@RamCharanji) January 11, 2018
Global Fibromyalgia Drugs market 2020: focuses on companies, opportunities, market size, growth, revenue & forecast 2026 | COVID19 Impact Analysis | Key Players: Pfizer, Eli Lilly, Actavis, Merck Sharp and Dohme, Daiichi Sankyo, etc. | InForGrowth – The … https://t.co/Z61iSQQlKs
— FMS News bot (@fmsbot) October 2, 2020
Hyperlipidemia Market: Market Data, Industry Analysis, Size,Share 2027 | Leading Players- AstraZeneca, Sanofi, Merck & Co., Pfizer, Daiichi Sankyo Company https://t.co/Wbz8agTS65
— Harshad Ramesh Borde (@BordeHarshad) August 25, 2020
The Next Boom Sector: Cancer
Physiomics #PYC is a leading oncology consultancy using its proprietary state of the art Virtual Tumour technology to predict and better understand effects of cancer treatments
Clients:
Merck, Astellas, Bicycle, Valirx, Cyclacel, CellCentric etc pic.twitter.com/djRsMNxJsc— Stockonomist (@Stockonomist) September 28, 2020
Thanks to our @ANZUPtrials #bestofGUoncology #ANZUPGU19 sponsors – @IpsenGroup Astellas Oncology @AstraZeneca @MSD_Aus pic.twitter.com/WtTfQE1djd
— ANZUP (@ANZUPtrials) November 6, 2019
.@NICEComms has been busy with announcements today, rejecting Astellas’ #Xospata for a certain type of acute myeloid leukaemia (AML) and querying evidence for MSD's #Keytruda in head and neck cancer https://t.co/vFcLhQXJnT
— pharmaphorum (@pharmaphorum) January 15, 2020
MSD acquires Takeda’s Dunboyne manufacturing facility https://t.co/zOsjPUDhHN
— Silicon Republic (@siliconrepublic) August 10, 2020
MSD buys Takeda biologics medicines plant in Dunboyne https://t.co/IflH6PU1MF via @IrishTimesBiz
— Irish Times Business (@IrishTimesBiz) August 7, 2020
MSD to takeover Takeda's Dunboyne facility https://t.co/ACUOaUBlOd
— RTÉ Business (@RTEbusiness) August 7, 2020
This is a very welcome announcement from MSD and Takeda. https://t.co/C6aqYapp57
— Martin D Shanahan (@MartinDShanahan) August 7, 2020
Takeda acquired Tim Clackson's prev company, ARIAD, in '17 for $5.2 Billion. He had originally joined ARIAD in 1994. In addition to Takeda & Merck/MRL, German Merck's M Ventures & Ipsen's venture fund are also corporate VCs that invested in the B round. They moved 2 Waltham, MA https://t.co/OxT4HM5RxL
— Pearl Freier (@PearlF) March 2, 2020
Takeda & Merck (MRL Ventures) r 2 of the investors in #CambMA-based immuno-oncology Xilio Therapeutics fka Akrevia. $100.5M B. Originally launched by @atlasventure & F-Prime. CEO is @OtherReneRusso & Tim Clackson is Prez & EVP R&D.MRL Ventures @dud3k BOD https://t.co/JaUnc6UUXD
— Pearl Freier (@PearlF) March 2, 2020
Takeda, Merck invest in cancer startup's Xilio Therapeutics $100M Series B round – Bizwomen https://t.co/GBIVu54ivm #venturecapital #earlystageinvestors #angelinvestors #startups
— Red Trait Ventures (@RedTrait) March 4, 2020
PharmaScrip: Executives On The Move: Exits From Takeda Vaccines And Novartis Institutes To CMO Positions And Board Changes At Merck & Co. https://t.co/1Ah2xcjDQI #PharmaScrip https://t.co/3BT9hqerzu pic.twitter.com/ON8dj4Klug
— ZorgNL (@zorgnl) February 13, 2020
Impact of COVID-19 on Colorectal Cancer Therapeutics Market Latest trending report is booming globally by Top Leading Players Taiho Pharma, Merck KGaA, Amgen, Takeda https://t.co/Xud5IlkmE0
— mednetnews (@mednetnews) October 17, 2020
Colorectal Cancer Therapeutics Market 2020-2026 | Comprehensive Study COVID19 Impact Analysis | Worldwide Key Players: Taiho Pharma, Merck KGaA, Amgen, Takeda, Roche, etc. https://t.co/rJMqyCbJPm
— mednetnews (@mednetnews) September 5, 2020
Global Innovative Drug Market Expected to Reach highest CAGR: Pfizer,Gilead Sciences,Johnson & Johnson,Roche,AbbVie,Sanofi,Amgen,Novartis,Merck & Co. (MSD),GlaxoSmithKline (GSK),Bayer,Takeda,AstraZeneca,Novo Nordisk https://t.co/An4NCt3fo9
— @ReportsandMarkets (@ReportsMarkets) October 13, 2020
#VaccinesEurope represents drugmakers including #AstraZeneca, #GlaxoSmithKline, #Janssen (which belongs to Johnson & Johnson), #Merck, #Novavax, #Pfizer, #Sanofi, #Takeda, #Abbott and #CureVac. Covid-19 vaccine makers #LobbyEU for #LegalProtection.https://t.co/FNImlmq8yE
— Riikka Kevo (@riikka_kevo) August 26, 2020
Lipid Metabolism Disease Drug Market Latest updates and Coronavirus (COVID-19) Impact on Global Market in 2020-2029 Merck, Takeda Pharmaceutical and Novartis – The Loop 21 https://t.co/xazRpkLaZ2
— Dr Jitesh Arora (@drjitesharora) July 29, 2020
Who would want a simple solution?
"thank the leadership of AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eisai, Eli Lilly, Evotec, Gilead, GlaxoSmithKline, Johnson & Johnson, KSQ Therapeutics, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda, and Vir"https://t.co/V20z6DAu2U
— sandeep chakraborty (@sanchak74) June 12, 2020
Global #pharmaceuticals unprecedented collaboration in the search for effective #COVID19 therapies. IFPMA press conference on 30 April 2020 with key speakers across MSD, Takeda, CSL, Pfizer, AstraZeneca, Sandoz and Merck.https://t.co/Blg8sI0uHX@IFPMA @ThomasCueni @MedicinesAus
— Rozalina Sarkezians (@RozalinaRS) May 1, 2020
Pray to Merck, Pfizer, Sanofi, Takeda, J&J, Lilly. Pray to all the start up biotechnology firms throughout the world. Pray to science. An imaginary friend in the sky will not help you. https://t.co/jGz1Ga4fID
— The Grackle ☠ (@LanceMa89524580) March 20, 2020
Takeda, Merck invest in Waltham cancer startup's $100M round https://t.co/KOtqmEQWpy
— Matthew Liptak (@mattliptak) March 2, 2020
Global Drugs for Lipid Metabolism Disease Market 2020 Raises During Pandemic Phase 2021 | Merck, Novartis, Takeda Pharmaceutical – Best News Monitoring https://t.co/6mUdaMY12P
— Dr Jitesh Arora (@drjitesharora) July 29, 2020
Skyhawk Therapeutics, one of GGC's first portfolio companies, recognized by BostInno as one of the 20 Boston Startups to Watch in 2020! Great progress on HUGE dollar contracts with Celgene / Bristol-Myers Squibb, Biogen, Merck, Takeda and Genentech. https://t.co/cktw5pUivN
— Good Growth Capital (@goodgrowthvc) December 23, 2019
U.K. イギリス Vol.30（pharmaceutical corporations 製薬会社）
All the below link and tweets are in English.
取り急ぎ以下貼っておきます。
UK Vol.169 (pharmaceutical corporations: AstraZeneca)
追加（本日までのツイート）
White blood cells produce antibodies in response to infection. Over 25 years, @croweje and @VUMC_Vaccines have pioneered techniques for isolating human “monoclonal” antibodies to neutralize pathogenic viruses with a laser-like focus. #COVID19 @AstraZeneca https://t.co/yomHmoGDpW
— VUMC Insights (@VUMC_Insights) October 14, 2020
Read Heather Macdonald-Tait’s account of what motivated her to volunteer for a trial of the #COVID19 vaccine developed by @UniofOxford and @AstraZeneca, and her experiences so far: https://t.co/LYpCFkxVbE
— Gavi, the Vaccine Alliance (@gavi) October 14, 2020
US Signs Deal With @AstraZeneca to Develop, Make #COVID19 Antibody Treatment
Learn more: https://t.co/oJncXqIEB1 pic.twitter.com/Bb8LWIbq5o
— AJMC (@AJMC_Journal) October 10, 2020
We’re partnering w/ @JPEOCBRND & @AstraZeneca under #WarpSpeed on clinical trials and large-scale manufacturing of a monoclonal antibody therapeutic to prevent #COVID19. With @US_FDA authorization, the doses could be used to help fight the pandemic https://t.co/ugxfm9LQyw pic.twitter.com/TUHAQMtLNU
— BARDA (@BARDA) October 9, 2020
.@BARDA, @JPEOCBRND & @AstraZeneca are working together at #WarpSpeed on clinical trials and large-scale manufacturing of a medicine to prevent #COVID19. The government will own these first doses and can make them available with authorization from @US_FDA. https://t.co/7LP5tF4rCf pic.twitter.com/924YcaCEvW
— ASPR (@PHEgov) October 9, 2020
Due to a month-long halt of the trial imposed by #US regulators investigating potential side-effects, volunteers have only been given one dose of the vaccine #COVID19 #Oxford @AstraZeneca https://t.co/NYt8lWVaHM
— Arab News (@arabnews) October 7, 2020
US Govt has awarded $486 million to @AstraZeneca PLC to develop & secure supplies of up to 1 lk doses of #COVID19 antibody treatment, a similar class of drug that was used in treating President #Trump: US Health Dept@realDonaldTrump @AstraZenecaUS pic.twitter.com/ahDVDSne3n
— ET NOW (@ETNOWlive) October 12, 2020
The U.S. government and @AstraZeneca have teamed up to develop 100,000 doses of #COVID19 antibody treatments for high-risk populations, with the possibility for the U.S. to acquire an additional 1,000,000 doses in 2021.
Learn more, via @CNBC https://t.co/A22Y0hOkLp
— Solomon McCown & Cence (@solomonmccown) October 12, 2020
A #COVID19 #vaccine trial by @UniofOxford and @AstraZeneca was paused last month due to a reported side effect in a patient.
But how common is pausing a vaccine trial? How does the trial resume? Do vaccine companies really treat safety seriously?@Dr_Banika explains: pic.twitter.com/3nkwwA9pLy— hospital research (@hosp_research) October 13, 2020
.@AstraZeneca received $1.2 BILLION to develop a #COVID19 vaccine from the US government. But that didn't satisfy their greed.
Since their Texas-sized payday, the company announced price hikes on many of their products TWICE. https://t.co/GdaTXQnzJk
— Texans For Affordable Rx (@TX4AffordableRx) October 8, 2020
After @Novartis & @AstraZeneca J&J puts on hold it’s #COVID19 trial due to unexplained illness in participant… All this isn’t surprising. Beyond the hype, reality of #clinicaltrials catches up with us… It’s a long, risky & unpredictable endeavor. https://t.co/YWV56CNFqA
— Amine Korchi MD (@AmineKorchiMD) October 13, 2020
#US, @AstraZeneca sign pact for #COVID19 antibody treatment used to treat #Trump https://t.co/ulVrswN2gD | #pharma #pharmanews #IndiaIncfightsCovid19
— ExpPharma (@ExpPharma) October 11, 2020
Let's talk about some real COVID19 drugs for a moment. The one drug that really helped me in my own COVID19 infection was Symbiocort by @AstraZeneca. I already had some at home for my asthma: my doc in Canada had given me a free sample he'd gotten from his drug rep. 1/ https://t.co/AKb6IAi6Y2
— Shawn Wenzel (@shawnwenzel) October 8, 2020
“Front-runners @Pfizer and @AstraZeneca say they have no plans to do challenge studies. Other #vaccine makers like @JNJNews are eyeing them cautiously… @moderna_tx has started manufacturing a strain of the virus that could be used for challenge studies…” #COVID19 #compliance https://t.co/McIgobW16i
— Mark Warner (@MAAWLAW) October 13, 2020
US backs @AstraZeneca #COVID19 antibody drug with $486M in funding. Read more at: https://t.co/tsxzEXmJIv
—#biomanufacturing #biopharma #pharmaceutical #pharma #vaccine pic.twitter.com/feSd63P3Qm
— American Biomanufacturing (@BioMfg) October 13, 2020
Pharma continue to hold the reins. "MoU between @AstraZeneca and a Brazilian manufacturer, which has been seen by @financialtimes, defines the “Pandemic Period” as ending on July 1 2021." #COVID19
https://t.co/2iBoiiC4Gz— Shailly Gupta (@Shaillytweeting) October 7, 2020
Mergers & Acquisitions explores 5 ways the #coronavirus is changing #dealmaking, as pharmaceutical companies such as @sanofi and @astrazeneca scramble to develop vaccines, diagnostic tools and treatments https://t.co/wvz94Eh9iZ
— Mergers&Acquisitions (@TheMiddleMarket) October 7, 2020
EMA begins real-time review of @AstraZeneca's #COVID19 vaccine: https://t.co/lHiEaN1tfE @EMA_News #clinicaltrials #COVID #CoronaVirus #Vaccine
— Teckro (@teckroofficial) October 9, 2020
Cambridge trio accelerate COVID-19 initiatives https://t.co/cLkjZ8M5oH @AstraZeneca @GileadSciences @sanofi @UniofOxford #COVID19 #coronavirus #Remdesivir pic.twitter.com/pfmZB60RxB
— Business Weekly (@businessweekly) October 8, 2020
Great news. The two vaccines for COVID-19: One is being developed by the company @AstraZeneca, Cambridge, UK, in collaboration with the University of Oxford, the other by @BioNTech_Group, Mainz, Germany, in collaboration with @pfizer, NY, USA. #COVID19. By @ChemistryViews https://t.co/sNXkzsF82d
— Química y Sociedad (@ForoQyS) October 8, 2020
Staffordshire is set to receive 600,000 doses of coronavirus vaccination from as early as November! It's great to hear that a vaccine to combat #COVID19 is being manufactured @KeeleUniversity following an agreement between @CobraBiologics & @AstraZeneca UK https://t.co/eXw21WRYO5
— Croft Architecture (@CroftArchitects) October 8, 2020
AstraZeneca eligible for provisional registration of Covid-19 vaccine after ruling by Therapeutic Goods Administration. News via @CanberraIQ for your daily news digest. For a free trial: https://t.co/jLzrWSAOYG @TGAgovau @AstraZeneca #COVID19 #pandemic https://t.co/hGDtvFgyl5
— Canberra IQ (@CanberraIQ) October 11, 2020
A vaccine to treat COVID-19 globally is imminent but its likely effectiveness has been laid bare. @AstraZeneca @pfizer @JennerInstitute #COVIDVaccine #Vaccinehttps://t.co/iir1So9X2O
— The CEO Magazine (@TheCEOMagazineG) October 14, 2020
ツイッター検索で 上記製薬会社 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの
We are thrilled to be building on our long-standing heritage in breast cancer through our collaboration announced today with Daiichi Sankyo. To learn more about why we believe pioneering new treatments in this area are so important, click here: https://t.co/1Haz3gHlud pic.twitter.com/pkXJnovNgz
— AstraZeneca (@AstraZeneca) March 29, 2019
AstraZeneca-Daiichi Sankyo's gastric cancer drug wins approval in Japan @AstraZeneca #daiichisankyo https://t.co/n2VmONPEKA pic.twitter.com/oaN0SVZtB1
— Market Intelligence: Healthcare (@SPGMIHealthcare) September 28, 2020
AstraZeneca to pay Daiichi Sankyo $1B up front in #cancer drug collaboration @AstraZeneca @DaiichiSankyo #dealmakinghttps://t.co/HjFewEzOS1 pic.twitter.com/8gdC72bRiM
— Market Intelligence: Healthcare (@SPGMIHealthcare) July 27, 2020
AstraZeneca-Daiichi Sankyo drug gets US FDA breakthrough tag for lung #cancer @AstraZeneca #enhertu https://t.co/8JOmhiH3dh pic.twitter.com/Gg2Bcxhuat
— Market Intelligence: Healthcare (@SPGMIHealthcare) May 18, 2020
COVID-19 Vaccine: AstraZeneca AZD1222 phase 1/2 trials to begin in Japan @AstraZeneca,@DaiichiSankyo #astrazeneca #astrazenecanews #clinicaltrial #coronavirus #covid-19 #coronavirusvaccine #azd1222 #daiichisankyo #jcrpharma https://t.co/ndeokzCfcI
— Medical Dialogues (@medicaldialogs) September 6, 2020
AstraZeneca, Daiichi Sankyo gets USFDA Breakthrough Therapy status for lung cancer drug Enhertu @AstraZeneca,@DaiichiSankyo #astrazeneca #cancer #enhertu https://t.co/6pyPdJqecP
— Medical Dialogues (@medicaldialogs) May 19, 2020
.@AstraZeneca has agreed a global development and #commercialization deal with @DaiichiSankyoUS, worth up to $6 billion for the Japanese #pharma. The deal centers on Daiichi Sankyo’s TROP2-directed antibody drug conjugate DS-1062 https://t.co/VC2DGKjyWP pic.twitter.com/BA6qSTSzWf
— CHEManager International (@CHEManager_EU) August 6, 2020
.@AstraZeneca has agreed to develop .@DaiichiSankyoUK Phase I cancer antibody drug conjugate DS-1062 worldwide except Japanhttps://t.co/jeq0LARzDm
DS-1062 is a trophoblast cell-surface antigen 2 -directed ADC for non-small cell lung cancer and triple negative breast cancer.— Decipher Analytics (@DecipherAnalyt2) July 30, 2020
@AstraZeneca bets up to $6 billion on new Daiichi cancer drug.https://t.co/CvDOIuBdVj
— TheNewsPanels (@TheNewsPanels) July 29, 2020
A look at some of the success factors behind yesterday's mammoth ADC deal with @AstraZeneca #pharma #biotech
Oncology Deal-Making The Daiichi Way https://t.co/NPnpZgejGG
— Ian Haydock (@ScripIanHaydock) July 28, 2020
AstraZeneca bets $1B on Daiichi rival to Immunomedics' Trodelvy | @AstraZeneca @ImmunomedicInc @Pfizer @DaiichiSankyo #pancsm #lungcancer #cancer #breastcancer #Biotech #NewJersey https://t.co/QV27IJeUjW
— Aspen Biosciences (@aspenbio) July 27, 2020
AstraZeneca & Daiichi Sankyo enter collaboration to develop and commercialise new ADC https://t.co/c3BBGtcTba @AstraZeneca @EUdaiichisankyo More European life science business news at [LSE] at https://t.co/df6Gi5dTPT pic.twitter.com/E3kdckFgzF
— [iito] Life Science (@iitoLifeScience) July 27, 2020
.@AstraZeneca pays $1B upfront & ~$5B milestones to codevelop DS-1062 w/ @DaiichiSankyo outside of Japan
TROP2-directed DXd #antibody-drug conjugate is currently in Ph1 #clinicaltrials vs #NSCLC & #TNBChttps://t.co/pXa46t3W6S#immunooncology #ADC #LungCancer #BreastCancer pic.twitter.com/jjm8bKCcyb
— DDNews Online (@DDNewsOnline) July 27, 2020
@AstraZeneca strengthens Daiichi Sankyo partnership with new development of a novel antibody drug conjugate (ADC) for the treatment of a number of multiple tumours which express the cell-surface glycoprotein TROP2https://t.co/aUefWC4btv vía @pmlivecom
— Jose Antonio Gasquet (@jagasquet) July 27, 2020
.@AstraZeneca & Daiichi have also been in talks over the supply of the British company's potential coronavirus vaccine in Japan.https://t.co/k1kqx6uYuL
— CNBC-TV18 (@CNBCTV18Live) July 27, 2020
.@AstraZeneca could pay up to $6 billion to #Japan's Daiichi Sankyo to develop and market a type of targeted cancer treatment in the second multi-billion dollar #cancer drug collaboration between the two companies.https://t.co/5CoLjHOdY9
— The Jerusalem Post (@Jerusalem_Post) July 27, 2020
AstraZeneca Collaborates with Daiichi Sankyo to Evaluate the Combination of Patritumab Deruxtecan (U3-1402) + Tagrisso for EGFR-Mutated Non-Small Cell Lung Cancer @AstraZeneca @DaiichiSankyoUS https://t.co/GegHhaEVis pic.twitter.com/y5XRj56gWY
— PharmaShots – Incisive news in 3 shots (@Pharmashot) August 7, 2020
Daiichi Sankyo in Talks with AstraZeneca for the Supply of AZD1222 to Combat COVID-19 in Japan @AstraZeneca @DaiichiSankyohttps://t.co/xcsgbutsPz pic.twitter.com/T6p9mCQ6YE
— PharmaShots – Incisive news in 3 shots (@Pharmashot) June 29, 2020
AstraZeneca and Daiichi Sankyo Provide Updates of Enhertu (fam-trastuzumab deruxtecan-nxki) in HER2-Positive Metastatic Colorectal Cancer and HER2-Mutant Non-Small Cell Lung Cancer #ASCO20 @AstraZeneca @ASCO https://t.co/ukMWYKFZfo pic.twitter.com/SjMNX4tMH6
— PharmaShots – Incisive news in 3 shots (@Pharmashot) June 1, 2020
AstraZeneca Signs a Worldwide Development and Commercialization Agreement with Daiichi Sankyo for $6.9B @AstraZeneca
https://t.co/zV274HcNZW— PharmaShots – Incisive news in 3 shots (@Pharmashot) April 1, 2019
One of @AstraZeneca's most decisive moves last year came when it signed a multi-billion dollar deal with @EUdaiichisankyo, focused on just one breast cancer drug. We spoke with Daiichi's @GillesJAGallant about the future plans for the drug https://t.co/C4VAEammCR pic.twitter.com/6NeXkiU5Kf
— pharmaphorum (@pharmaphorum) January 30, 2020
Results from a piviotal study of @AstraZeneca and Daiichi Sankyo’s trastuzumab deruxtecan, showed that women with breast cancer who had not responded to around six prior treatment courses saw no further progression for a median of 16.4 months https://t.co/TL1sLOmgf6
— pharmaphorum (@pharmaphorum) December 12, 2019
AstraZeneca, Daiichi Sankyo get Orphan Drug Designation for gastric cancer drug Enhertu @AstraZeneca #astrazeneca #enhertu #usfda #daiichisankyo #gastriccancer #trastuzumabderuxtecan https://t.co/ofKbiL4T8M
— Medical Dialogues (@medicaldialogs) May 25, 2020
Rare disease: Enhertu of @AstraZeneca and Daiichi Sankyo now with Orphan Drug Designation in the US for treatment of gastric cancer https://t.co/IZqqD1DNTf #gastricCancer #rarediseases #cancers #oncology pic.twitter.com/npY2FpPoZF
— EuropaWire (@europawire) May 22, 2020
From the Center for Biosimilars, @AstraZeneca + Daiichi-Sankyo win @US_FDA OK for #trastuzumab antibody conjugate #Enhertu https://t.co/s2E3s6bSr8
— AJMC-Oncology (@EBOncology) December 23, 2019
FDA accepts BLA from AstraZeneca and Daiichi for targeted chemotherapy@AstraZeneca @DaiichiSankyo #oncologydrugs #targetedchemotherapy https://t.co/NB0YHsLwUI
— Pharma Tech Focus (@PharmaTechFocus) October 18, 2019
AstraZeneca and Daiichi Sankyo sign $6.9bn cancer drug development deal @AstraZeneca @EUdaiichisankyo #cancerdrugdevelopment #bigpharmadealtshttps://t.co/lWXBRDSHS8
— Pharma Tech Focus (@PharmaTechFocus) March 29, 2019
Full house at AstraZeneca Exchange event at the Judge Business School, University of Cambridge. Fascinating insight to the recent AZ/Daiichi Sankyo deal from the people who made it happen @AstraZeneca @CambridgeJBS pic.twitter.com/CaN7n8PAw2
— Milner Institute (@TheMilnerInst) July 3, 2019
@AstraZeneca and Daiichi's #HER2 ADC hits goal in pivotal trial https://t.co/E0rhjfKnGX
— Miles Collier (@MilesCollier) May 8, 2019
.@AstraZeneca has signed a $6.9bn collaboration with Daiichi Sankyo to co-partner on cancer drug DS8201. Read full note here @LiberumToday #aim #shareshttps://t.co/R2styv9Pxs pic.twitter.com/trsEc3uZiW
— Research Tree (@research_tree) April 5, 2019
@AstraZeneca signs $6.9B deal with Daiichi Sankyo for #cancertherapy #healthcare #news https://t.co/kw2IhwuIBT
— Healthcare Opportunities (@HealthcareOppo1) April 3, 2019
.@AstraZeneca will pay up to $6.9 billion in #cancer drug deal with Daiichi and more for #pharma #marketers to know. #drugprices #DTC $JNJ $AZN $GILD https://t.co/CIJqaYE6LJ pic.twitter.com/j6VKJgbvgW
— MM+M Magazine (@MMMnews) April 1, 2019
.@AstraZeneca and Daiichi Sankyo brought us a huge deal last night. We worked on the Top 20 #cancer deals with @JohnCendpts at @endpts with data from @DealForma $AZNhttps://t.co/HJjEAS19Gz
— Chris Dokomajilar (@ChrisDoko) March 29, 2019
.@AstraZeneca sought to buy Japan's Daiichi Sankyo last year https://t.co/BQ6IFBwu8l pic.twitter.com/s933R4Glvb
— The Business Times (@BusinessTimes) August 31, 2017
#AZN £85.95 #AI #PHARMA$AZN & Daiichi Sankyo enter collaboration to develop & commercialise new #antibody drug✅
Calquence recommended for approval in the EU for chronic #leukaemia✅
Imfinzi recommended for approval in the EU for small cell lung #cancer✅https://t.co/pRRm18hjeI pic.twitter.com/uHD3PLkvay— Peter Higgins (conkers) (@conkers3) July 27, 2020
#AZN-4% £62.05 $3.5Bn #Placing & collaboration w/ Daiichi Sankyo for #HER2 ADC #trastuzumab deruxtecan (DS-8201) w/ upfront payment of $1.35B, plus up to $5.55B include $3.8B for regulatory & other milestones, as well as $1.75B for sales-related milestones https://t.co/Lj8lTxIsdL pic.twitter.com/YmjCiZF2TR
— Peter Higgins (conkers) (@conkers3) March 29, 2019
AstraZeneca Resumes Clinical Study of its COVID-19 Vaccine in Japan @AstraZeneca https://t.co/l8IrrMu0oz pic.twitter.com/Wyn0BkNSKz
— PharmaShots – Incisive news in 3 shots (@Pharmashot) October 5, 2020
AstraZeneca and MSD’s Selumetinib Receive MHLW’s Orphan Drug Designation for Neurofibromatosis Type 1 in Japan @AstraZeneca @Merck https://t.co/azsnR93iP5 pic.twitter.com/34oe5UGj9p
— PharmaShots – Incisive news in 3 shots (@Pharmashot) June 30, 2020
.@AstraZeneca Plc said on Friday clinical trials of its experimental COVID-19 #vaccine resumed in Japan.https://t.co/enubUg9VQ6 pic.twitter.com/bSDa4lRQTp
— Arab News Japan (@ArabNewsjp) October 3, 2020
Major British drugmaker @AstraZeneca PLC said Friday that it has agreed with the Japanese government to launch negotiations on supplying #Japan with a #coronavirus vaccine currently under development with University of Oxford.https://t.co/OTrkWJzmHn pic.twitter.com/MYMrK1ZReE
— Arab News Japan (@ArabNewsjp) June 27, 2020
Japan's Prime Minister @AbeShinzo said Sunday that the country is in talks with pharmaceutical firms overseas to secure vaccines for the novel #coronavirus towards the end of the year.@AstraZenecahttps://t.co/k41GZj2afH pic.twitter.com/hKODrfAh5O
— Arab News Japan (@ArabNewsjp) June 14, 2020
.@AstraZeneca resumes #COVID19 #vaccine trial in Japan, U.S. still paused. https://t.co/reQEFIZw5M
— A Voice For Choice Advocacy (@avoiceforchoice) October 2, 2020
https://twitter.com/moneycontrolcom/status/1311949554284023808
Kudos to @AstraZeneca whose Breztri Aerospher has become the first triple-combination therapy for #COPD in a pressurized metered-dose #inhaler device to be approved in Japan. https://t.co/9KlWUm8B8t #NoblePharma #GoNoble
— Noble (@NoblePharma) August 9, 2019
Latest newsletter highlights: VivaGel BV European & AU launch, $SPL’s 2nd @AstraZeneca agreement, VivaGel condom launch in Japan w/ @Okamototown & our DEP programs https://t.co/mOVSIwGRZ6 #ASX pic.twitter.com/jK9jN33tY9
— Starpharma (@Starpharma_ASX) July 1, 2019
#AstraZeneca Reports Approval Of #Tagrisso In #Japan https://t.co/yEwHkUDRvG @RTTNews @AstraZeneca #osimertinib #NSCLC
— Plexus Ventures (@PlexusVentures) August 22, 2018
In industry news: Lynparza Approved in Japan for BRCA-Mutated Metastatic #BreastCancer @AstraZeneca @Merck https://t.co/rYdVMDnSfm pic.twitter.com/GEOQrnCUeQ
— Mammary Cell News (@MammaryCell) July 6, 2018
What possibilities for business with the #EU #Japan free trade agreement? Highly relevant seminar in Stockholm today by @BusinessSweden and @SweMFA, with opening by @AnnLinde. @AstraZeneca @BabyBjornSweden @Virtusize @Kommerskoll pic.twitter.com/D9A92vi2tC
— Anna Stellinger (@AnnaStellinger) March 28, 2018
Inflammatory Intestinal Diseases Findings: Efficacy & Safety of Oral #Budesonide in Patients with Active #Crohn's Disease in Japan: A Multicenter, Double-Blind, Randomized, Parallel-Group Phase 3 Study #Crohns @AstraZenecaSE @AstraZeneca @S_Karger_Japanhttps://t.co/bejGi7Mmg5 pic.twitter.com/hZnd8trekI
— Karger Open Access (@KargerOpen) November 28, 2017
Our employees from around the globe did their bit for #EarthDay at the weekend, with teams from Serbia, to Japan & the US joining the #EarthDayCleanUp19. Find out more about our approach to environmental protection as part of our sustainability strategy: https://t.co/1wtTM2Z3xp. pic.twitter.com/N2xBB4hMvh
— AstraZeneca (@AstraZeneca) April 25, 2019
Did you know that we have committed to moving 100% of our vehicle fleet across Europe, North America & Japan to hybrid, plug-in or electric by 2025? This is one of the ways we are working to #ActOnClimate earning us a spot on the @CDP #CDPAList: https://t.co/1g9MJYeXD3 pic.twitter.com/1KbqbupS7C
— AstraZeneca (@AstraZeneca) February 25, 2019
https://twitter.com/BCCJapan/status/1193767882334687232
https://twitter.com/BCCJapan/status/1071924366328258560
Phase III and Phase II/III clinical trials studying immunization for #RSV disease prevention for all infants have launched in Japan. We are pleased to partner with @AstraZeneca in an effort to reduce the burden of #RSV worldwide. Learn more here: https://t.co/a7KpuD4M4Z pic.twitter.com/7ven9yqeHK
— Sanofi (@sanofi) October 11, 2019
Astrazeneca Pharma initiates the commercial launch of XIGDUOA XR tablets in India. XIGDUOA XR is a product of @AstraZeneca Group approved in 61 countries including US, EU & Japan. It is used to treat type 2 diabetes mellitus pic.twitter.com/JqEBOjh5dJ
— CNBC-TV18 (@CNBCTV18Live) February 12, 2018
.@AstraZeneca enters agreement with Kyowa Hakko Kirin to commercialise antibody to treat asthma/COPD in Japan http://t.co/3yBVniGTW0 #pharma
— SartoriusRoyston (@TAPBiosystems) July 18, 2015
Grünenthal to Acquire AstraZeneca’s European rights to Nexium & Global (ex US & Japan) Rights to Vimovo for up to $922m https://t.co/uAVjxWY3IX @grunenthalgroup @AstraZeneca More European life science business news at [LSE] at https://t.co/8to5cxePG5 pic.twitter.com/lceOUo8wHH
— [iito] Life Science (@iitoLifeScience) October 30, 2018
AstraZeneca: Tagrisso Approved in Japan for 1st-line EGFR-mutated NSCLC https://t.co/FRUMYxZIYx @AstraZeneca More UK & Irish life science business news at [LSE] at https://t.co/ShKV2svWTv pic.twitter.com/XDjdQn2XTd
— [iito] Life Science (@iitoLifeScience) August 21, 2018
#AZN £63.74 After positive news: #Calquence trial✅#Lynparza approved in the #EU✅#Bevespi #Aerosphere approved by the #Japanese MH✅
Lynparza approved in #Japan✅
Breztri Aerosphere (PT010) approved in Japan✅https://t.co/pRRm18hjeI #COPD #PHARMA #AI pic.twitter.com/z0rSyl0eqz— Peter Higgins (conkers) (@conkers3) June 19, 2019
#AZN £59.90 #Tagrisso approved in #Japan for 1st-line treatment of EGFR-mutated non-small cell lung #cancer.
1st-line Tagrisso offers a potential new standard of care for Japanese lung cancer patients✅https://t.co/C8ZDZK9cuV #PHARMA #BIOTECH #BIOPHARMA #MEDTECH #AI #ML #SCIENCE pic.twitter.com/vCp7Y2yiWn— Peter Higgins (conkers) (@conkers3) August 21, 2018
#AZN +2% £53.59$AZN Regulatory submission in #Japan for #Forxiga in type-1 #diabetes✅ https://t.co/TLiZLg7L6I
US regulators finally approve @AstraZeneca' potential blockbuster #LOKELMA drug✅https://t.co/GDxPfuUR0D #PHARMA #BIOTECH #INVESTING #QARP pic.twitter.com/0P5FEP3J0E
— Peter Higgins (conkers) (@conkers3) May 21, 2018
#AZN+1% £50.36 @DigitalLookNews #AstraZeneca gets approvals for #Fasenra & #Lynparza in #Japan✅Lynparza is the first poly ADP-ribose polymerase (PARP) inhibitor to be approved in Japan✅ https://t.co/ErNbKkH0YE #bronchial #asthma #COPD $AZN #PHARMA #BIOTECH #BIOPHARMA #MEDTECH pic.twitter.com/QLyA8r41IC
— Peter Higgins (conkers) (@conkers3) January 19, 2018
.@AstraZeneca Q1 Results http://t.co/eYQpCrJ12W Growth platforms (Brilinta, diabetes, respiratory, Emerging Markets & Japan) +13% to $3.4Bn
— Peter Higgins (conkers) (@conkers3) April 24, 2015
#DRG epidemiology report estimates more than 35,000 newly diagnosed cases of #chroniclymphocyticleukemia across the United States, Western Europe and Japan. Detailed global reports available now @DRGinsights #CLL #leukemia chronic #lymphocyticleukemia @AstraZeneca https://t.co/c93A2A45xs
— DRG Epidemiology (@DRG_Epi) December 2, 2019
#DRG epidemiology report estimates more than 3.5 million people affected with #hyperkalemia across the United States, Western Europe and Japan. Detailed report available now @DRGinsights #kidney #KidneyWk #chronickidneydisease @AstraZeneca https://t.co/PV3qywDoqv
— DRG Epidemiology (@DRG_Epi) November 18, 2019
#DRG epidemiology report estimates over 35,000 newly diagnosed cases of #chroniclymphocyticleukemia across the United States, Western Europe and Japan. Detailed global reports available now @DRGinsights #CLL #leukemia #lymphocyticleukemia #BloodCancerAwarenessMonth @AstraZeneca https://t.co/a86N2RqLkg
— DRG Epidemiology (@DRG_Epi) September 11, 2019
More than 7000 newly diagnosed #ovariancancer cases have #BRCA #mutations across the United States, Western Europe and Japan. Watch this space for more updates on #DRG global epidemiology data @DRGinsights #ovarian #cancer #biomarkers #tumors #genetictesting @AstraZeneca https://t.co/X2aYXDRkqQ
— DRG Epidemiology (@DRG_Epi) September 3, 2019
#DRG epidemiology report estimates more than 35,000 newly diagnosed cases of #chroniclymphocyticleukemia across the United States, Western Europe and Japan. Detailed global reports available now @DRGinsights #CLL #leukemia chronic #lymphocyticleukemia @AstraZeneca https://t.co/dIbsLkOrVa
— DRG Epidemiology (@DRG_Epi) August 22, 2019
More than 3.5 million people are affected with #hyperkalemia across the United States, Western Europe and Japan. Follow us for more updates on #DRG epidemiology data on #hyperkalemia #CKD @DRGinsights @AstraZeneca #KidneyWk https://t.co/xOVhUSaqVL
— DRG Epidemiology (@DRG_Epi) October 25, 2018
#DRG reports more than 10 million cases living with #Alzheimers across the United States, Western Europe and Japan https://t.co/r92nrjx1mO @DRGinsights @AstraZeneca https://t.co/xk3LFosS3Q
— DRG Epidemiology (@DRG_Epi) August 3, 2018
Thanks to our @ANZUPtrials #bestofGUoncology #ANZUPGU19 sponsors – @IpsenGroup Astellas Oncology @AstraZeneca @MSD_Aus pic.twitter.com/WtTfQE1djd
— ANZUP (@ANZUPtrials) November 6, 2019
Thanks also to our #APCCC APAC Satellite Symposium sponsors Astellas @AstraZeneca @IpsenGroup @JanssenANZ and Tolmar #APCCCinAPAC18 pic.twitter.com/AnrhNOAxuu
— ANZUP (@ANZUPtrials) February 23, 2018
.@MeetingsShow’s healthcare education speakers to include @AstraZeneca and Astellas: http://t.co/EtOBMyb9Q5 #TMS15 pic.twitter.com/xlnTvYk3fr
— Soaring Worldwide (@SoaringWW) June 16, 2015
United States Shingles Vaccine Market @SanofiPasteur,@GlaxoSmithKline,@Merck,@Pfizer,@AstraZeneca,@Mitsubishi,@EmergentBiosolutions,@Astellas,@Valneva,@Seqirus,@BavarianNordic,@Sinovac,@Panacea,@BharatBiotech #shingles #zoster #vaccine https://t.co/DIBnqocTp0 via @dpiresearch
— DPI Research (@DPIResearch) October 14, 2020
Vaccines Market Booming Worldwide With Leading Players https://t.co/yVs3yTmMC8 @SanofiPasteur,@GlaxoSmithKline,@Merck,@Pfizer,@AstraZeneca,@Mitsubishi,@EmergentBiosolutions,@Astellas,@Valneva,@Seqirus,@BavarianNordic,@Sinovac,@Panacea,@BharatBiotech
— DPI Research (@DPIResearch) September 28, 2020
United States Influenza Vaccines Market Forecast 2020 – 2027 https://t.co/ovFvfMYYfI @SanofiPasteur,@GlaxoSmithKline,@Merck,@Pfizer,@AstraZeneca,@Mitsubishi,@EmergentBiosolutions,@Astellas,@Valneva,@Seqirus,@BavarianNordic,@Sinovac,@Panacea,@BharatBiotech
— DPI Research Official (@dpi_research) August 28, 2020
I just published US Influenza(Flu) Vaccine Market https://t.co/I0te2HEkCW @SanofiPasteur,@GlaxoSmithKline,@Merck,@Pfizer,@AstraZeneca,@Mitsubishi,@EmergentBiosolutions,@Astellas,@Valneva,@Seqirus,@BavarianNordic,@Sinovac,@Panacea,@BharatBiotech
— DPI Research Official (@dpi_research) August 27, 2020
Analyst Keshalini Sabaratnam @Pharma_GD on the #sales #forecast for @Merck and #Otsuka 's #Keytruda (pembrolizumab) projected to be top drug by 2023 and what does this mean for their #contractmanufacturers #CDMO #CMO @AstraZeneca @BoehringerDE https://t.co/R6Wmwcm2Qb
— GlobalData PharmSource (@PharmSource) October 2, 2019
#Innovation #Index #Pharma @baxter_intl @Celgene #Otsuka @AstraZeneca @Roche @Novartis… https://t.co/zzzaGWoCii pic.twitter.com/sbAEuYm54a
— Biotechin.asia (@biotechinasia) April 10, 2016
AstraZeneca and Eisai make EMA demands:
The European Medicines Agency will relocate from the UK in light of Brexit. https://t.co/plD7JJnH1z @AstraZeneca #Eisai #EMA @EMA_News #Brexit #medicine #health #Lifesciences— LifeSciencesIPReview (@LifeSciencesIPR) January 10, 2018
.@AstraZeneca and Eisai support continued @EMA_News oversight of drugs and safety on both sides of the Channel. Minimum demand is “mutual recognition” of medicines standards. #Brexit https://t.co/2RNHEIPPMA
— RegMedNet (@RegMedNet) January 9, 2018
On #WorldNTDDay we celebrate our industry partnerships to #beatNTDs including the innovative Drug Discovery Booster to discover new drugs with @abbvie @AstellasUS @AstraZeneca @bmsnews @Eisai_SDGs @merckgroup Shionogi & @TakedaPharma. pic.twitter.com/j4Xgs60vO2
— Drugs for Neglected Diseases initiative (@DNDi) January 30, 2020
DNDi partners with Eisai, Shionogi, Takeda, and @AstraZeneca to find new treatments for #Chagas and #leishmaniasis http://t.co/ZA64pVAEhE
— Drugs for Neglected Diseases initiative (@DNDi) May 29, 2015
Huge thanks to @wellcometrust for having confidence in us. Terrific to be working in partnership with @turinginst to combine scientific excellence with commitment to improve the working environment for trainees with @NHSDigital @eisai @gsk @AstraZeneca @Microsoft @intel @iqvia https://t.co/bjIYmMhDH0
— Andrew Morris (@profadmorris) September 16, 2019
Excellent dialogue b/t #GlobalHealth leaders, philanthropic pharm. cos. @AstraZeneca @Eisai and NGOs @DND about partnerships to #CombatNTDs pic.twitter.com/jQwl8S8XAP
— MAP International (@mapintl) October 27, 2017
The 2020 Pharmaceutical Innovation and Invention Index is live at @FortuneMagazine: https://t.co/dLQhy8vDMF
2020 Innovation Index
1 @Roche
2 @abbvie
3 @Novartis
3 @VertexPharma
5 @LillyPad
6 @AstraZeneca
7 @AlexionPharma
8 @Merck
9 Shionogi
10 @JNJNews
10 @Regeneron— Mike Rea, IDEA Pharma (@ideapharma) April 6, 2020
.@purduepharma and Shionogi take on @AstraZeneca, @Valeant in opioid-induced constipation. https://t.co/KaqgT4sAnO #DrugApproval $AZN $VRX pic.twitter.com/LlFIXx79wf
— FiercePharma (@FiercePharma) March 24, 2017
Vaccines Market Booming Worldwide With Leading Players @SanofiPasteur @GSK @Merck @Pfizer @AstraZeneca @Mitsubishi @emergentbiosolu @AstellasPharma @Valneva @Seqirus @CSLLimited @BavarianNordic @Sinovac @PanaceaBiotec @Dynavax @Grifols https://t.co/G6av4krbos via @dpiresearch
— DPI Research (@DPIResearch) October 5, 2020
Check out my latest article: Flu Vaccines Market Worth $7.5bn by 2027
https://t.co/ZbzwVCpnrq via @LinkedIn @SanofiPasteur @GSK @Merck @Pfizer @AstraZeneca @Mitsubishi @EmergentBioSolutions@AstellasPharma @Valneva @Seqirus @CSLLimited @BavarianNordic @Sinovac @PanaceaBiotec— DPI Research (@DPIResearch) October 7, 2020
https://t.co/6rgVwPyvqg @SanofiPasteur @GSK @Merck @Pfizer @AstraZeneca @Mitsubishi @EmergentBioSolutions@AstellasPharma @Valneva @Seqirus @CSLLimited @BavarianNordic @Sinovac @PanaceaBiotec @Dynavax @Grifols
— DPI Research (@DPIResearch) October 11, 2020
#ImaginAb joins with #AstraZeneca, #Pfizer and #Takeda to develop #tumourimaging #tech https://t.co/ccUgDG0BiV via @pharmaphorum @AstraZeneca @pfizer @TakedaPharma #technology #immunotherapies
— Plexus Ventures (@PlexusVentures) October 14, 2019
“@Novavax has signed similar deals with the UK, India, the Czech Republic, South Africa & Japan to supply doses of the potential #vaccine… [The Canadian government] is also in the final stages of negotiations with drug firm @AstraZeneca…” #COVID19 https://t.co/1qusqAiqJQ
— Mark Warner (@MAAWLAW) August 31, 2020
Takeda teams up with Novavax to introduce its coronavirus vaccine in Japan | @Takedapharma @Novavax @Pfizer @BioNTech @AstraZeneca @UniofOxford #Vaccines #Covid19 #Biotech #MatrixM #Maryland #OperationWarpSpeed @JNJ https://t.co/82tpoKazFb
— Aspen Biosciences (@aspenbio) August 9, 2020
Experts at @Astrazeneca, @Takeda and @Novartis tell us how to strengthen the collaboration and improve trust with patient community https://t.co/2sffvRXmJE #patients #patientcentricity #efppatients pic.twitter.com/QCW22ABoH2
— The Pharmaceutical Marketing Group (@PharmaMKTnet) September 28, 2019
Wrote about @AstraZeneca's new $1 billion plan to go carbon-zero by 2025 (carbon-neutral by 2030), and just how bad US-based big Pharma is
(Other Pharmas with near-term carbon-neutral plans: Novo Nordisk, Takeda and Novartis, all 3 EU or Japan-based)https://t.co/eqmNeLflQv
— Jason Mast (@Jasonmmast) January 23, 2020
U.S.A. アメリカ Vol.107（New York ニューヨーク州 Vol.2: pharmaceutical corporations 製薬会社）
All the below links and tweets are in English.
取り急ぎ以下貼っておきます。
New York Vol.35 (corporations: Pfizer)
New York Vol.36 (corporations: Bristol Myers Squibb)
New York Vol.37 (corporations: Regeneron)
ツイッター検索で 上記3製薬会社各社 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの
AFIB awareness month – learn more here and spread the word. #Bayer #Daiichi-Sankyo #BMS #Pfizer https://t.co/v8seSL6y3u
— Medable (@medableinc) September 24, 2020
#XTANDI #news
Pfizer and Astellas announced the final results of the overall analysis from Phase 3 PROSPER study#asco20 #asco2020 #oncology #pharmanews #pfizer #astellas #conferences #consultingservices https://t.co/Tj2z4xc0rn— ipharmacenter (@ipharmacenter) May 30, 2020
Insights on the Worldwide Antihypertensive Drugs Industry to 2026 – Players Include Pfizer, Takeda Pharmaceutical & AstraZeneca Among Others – https://t.co/8vPVgQlQhj https://t.co/bzOL6dTM2O
— Pharmacutical Daily (@PharmacDaily) April 6, 2020
Pfizer, Astellas' Xtandi scores Bayer-matching win in extending prostate cancer patients' lives. Can Pfizer and Astellas leverage this data into building Xtandi as the market leader in castration-resistant #prostatecancer? #pcsm $PFE https://t.co/r6Qu9NOoll pic.twitter.com/8EiTRmgIxE
— Bionest Partners (@BionestPartners) February 12, 2020
FDA approves expanded label for Pfizer, Astellas' prostate cancer therapy Xtandi https://t.co/fCFTjO9ita
— Stuart Edmonds (@stuartd_e) December 19, 2019
Great turnout for our Siemens Sitrain TIA Portal Service 1 course. Patrick Martin from Siemens SITRAIN Manchester @siemensuknews was the trainer & participants came from #EirGen, #Pfizer, #Takeda & #IMALife. The course will run again in Feb '20: https://t.co/8uD3AVwAWq(tia-s.aspx pic.twitter.com/2FETEXmR6E
— Engineers Ireland (@EngineerIreland) December 5, 2019
ImaginAb joins with AZ, Pfizer and Takeda to develop tumour imaging tech, writes @pharmaphorum https://t.co/ZBtv9FxFG3
— ImaginAbInc (@ImaginAbInc) October 14, 2019
Pfizer, Astellas win priority review for Xtandi sNDA; Hemispherx changes its name https://t.co/p50wHHb5X1 $PFE
— Endpoints News (@endpts) August 24, 2019
Parenteral Nutrition Market 2019: Industry Analysis and Detailed Profiles of Top Industry Players B. Braun Melsungen AG, Fresenius Kabi AG, ALLERGAN, Grifols, S.A., Pfizer Inc., Otsuka Pharmaceutica https://t.co/Asz3gkZp3s pic.twitter.com/NfOrepvOzK
— PressRelease.cc (@PressRelease_cc) May 21, 2019
See how #Pfizer, #AstraZeneca, #Sanofi, #Astellas and more are achieving real patient centric processes in these free panels from our 2019 patient track https://t.co/RYUehW8IOL
— Reuters Events Pharma (@RE_Pharma) October 11, 2019
@pfizer or Otsuka. Which company do you admire the most? Vote here: https://t.co/2YWu39L6xM #mostadmiredpharma pic.twitter.com/WKI5AzT7pR
— Reuters Events Pharma (@RE_Pharma) January 10, 2017
#Pfizer, #Astellas’ #Xtandi significantly improves #OS in phase 3 #prostatecancer study https://t.co/Sl5SywJbvp via @Pharma_BR @pfizer @AstellasUS @pfizer_news
— Plexus Ventures (@PlexusVentures) February 13, 2020
Pfizer, Astellas' Xtandi scores Bayer-matching win in extending prostate cancer patients' lives https://t.co/6Cf4Ow9STS
— FiercePharma (@FiercePharma) February 11, 2020
J&J's Erleada scores metastatic prostate cancer nod in battle with Pfizer-Astellas' Xtandi https://t.co/Eig4GG22N9
— FiercePharma (@FiercePharma) September 18, 2019
Pfizer, Astellas rocket toward broader Xtandi use with FDA 'priority' tag https://t.co/KcOPOyolpw
— FiercePharma (@FiercePharma) August 22, 2019
Pfizer, Astellas chase new Xtandi nod with big survival numbers in prostate cancer https://t.co/x2nz46FY1l
— FiercePharma (@FiercePharma) February 12, 2019
The deals with Novartis, Otsuka, Pfizer and Sanofi will boost its ecosystem and “could help foster greater scientific discovery” as the pharma companies work on “next-generation research and development programs,” Verily said: https://t.co/h6tD7yJiaf
— FierceBiotech (@FierceBiotech) May 21, 2019
Prostate cancer shake-up looms with new data from Pfizer, Astellas and Johnson … https://t.co/reOTWifrUC $JNJ #stocks #stockmarket
— StockMarketScoop (@StockScoops) February 26, 2019
Japan has signed a deal to secure 120 million doses of a potential coronavirus vaccine, German pharmaceutical group BioNTech, which is developing the drug with US pharma giant Pfizer, said. https://t.co/crihB500gj
— Philstar.com (@PhilstarNews) August 1, 2020
More updates to @nytimes vaccine tracker: Sanofi makes a deal to supply US with protein vaccines, Pfizer makes a deal with Japan, Vaxine finishes Phase I trials, and monkeys get protection from Moderna and J&J shots. https://t.co/8RbPgaLziS
— Carl Zimmer (@carlzimmer) July 31, 2020
Pfizer, BioNTech to supply 120 million doses of coronavirus vaccine to Japan https://t.co/CPE5UL5WWR pic.twitter.com/iphKs1StYM
— Reuters (@Reuters) July 31, 2020
Pfizer Japan recalls high blood pressure drug over cancer-causing impurity https://t.co/9LdUeUtJi0 pic.twitter.com/mo0igvh0Hb
— Reuters (@Reuters) February 8, 2019
Pfizer Japan recalls its high blood pressure drug Amvalo containing the API valsartan after possible carcinogenic impurities were found. https://t.co/g7iIuIf8Wl
— ConsumerSafetyWatch (@consumersafetyw) February 11, 2019
Pfizer Japan drawn into valsartan recall after finding API from Mylan is tainted #Pharma https://t.co/6bR5IJSo4L
— Varadharajan K PhD (@VaradhKrish) February 13, 2019
Pfizer Japan Cautious Over New Policies As Sales Slip https://t.co/WCU1uOPqqO
— Ian Haydock (@ScripIanHaydock) March 2, 2018
Pfizer expands Japan contracting offering touting market knowhow https://t.co/5WwiesSuTE #onmedic #ehealth #pharma
— onmedic global (@onmedicglobal) October 23, 2017
From the Pfizer Photo Archives: A sales rep discusses medicines with a pharmacist in Nagoya, #Japan (1967) pic.twitter.com/b864XJQgSq
— Pfizer Inc. (@pfizer) March 5, 2016
From the Pfizer Photo Archives: Sales reps at Pfizer #Japan prepare for a busy day of appointments (1963) pic.twitter.com/lCLRWnW3wc
— Pfizer Inc. (@pfizer) February 6, 2016
Pfizer Japan matches PFE colleague donations to fund recovery efforts from devastating #NepalEarthquake pic.twitter.com/HoRjVNyJ0W
— Pfizer Inc. (@pfizer) August 21, 2015
Anti-Obesity Prescription Drugs Market Future Scenario, CAGR, Key Developments and Size|Bristol-Myers Squibb Co., Takeda Pharmaceutical., Eisai Company.https://t.co/UqYXeQUzeB#news #pharma #pharmiweb
— Pharma News (@pharminews) September 22, 2020
Bristol-Myers Squibb, Takeda and Daiichi Sankyo shot up rankings of top 20 pharma companies by market cap, according to a new GlobalData analysis https://t.co/EJc7SrNBnM
— pharmaphorum (@pharmaphorum) June 22, 2020
MedNess this week features bite size news on:
BioMarin’s hemophilia A candidate accepted for FDA priority review
Japan Approves Bristol-Myers Squibb's Opdivo for Esophageal Cancer
FDA Issues Complete Response Letter for sBLAs…https://t.co/oLDevWice6 https://t.co/AYfj4HBTeX
— Ananda Ghosh, PhD (@andz79) February 26, 2020
Professionals from Becton Dickinson, Astellas, Novartis, Bristol-Myers Squibb, and more convene at Novo Nordisk headquarters for the upcoming 15th Public Relations & Communications Summit. https://t.co/pCJ7YBFjlF
— Fierce Life Sciences Events (@LifeSciEvents) April 30, 2019
Roche says 'no thanks' to megadeals, but don't count out smaller M&A: After two recent, huge tie-ups between Takeda and Shire and Bristol-Myers Squibb and Celgene, megamergers seem to be a biopharma trend. But Roche isn't interested, its chairman said. https://t.co/BAAOw2Wgks
— cafepharma (@cafepharma) January 22, 2019
Taisho Pharmaceutical will acquire the French over-the-counter drugmaker UPSA from Bristol-Myers Squibb, the latest move by Japan's top seller of nonprescription medicines to expand overseas. https://t.co/hDgtCvt9Xr
— Nikkei Asian Review (@NAR) December 19, 2018
Immunosuppressants Market Impressive Growth 2019 | GlaxoSmithKline plc, Novartis AG, Sanofi, Bristol-Myers Squibb Company, Pfizer Inc., Astellas Pharma Inc., Zydus Cadila https://t.co/UgRU3aWvgK pic.twitter.com/zRdA3OAcP7
— ABNewswire (@ABNewswire) September 13, 2019
Thymus Cancer Market to Grow exponential with Astellas Pharma | Astrazeneca | Bristol-Myers Squibb | Takeda pharmaceutical company, etc. – Asserts MRFR Unleashing Industry Forecast to 2024 https://t.co/j0Lby60IiK pic.twitter.com/t40OOZcXlh
— ABNewswire (@ABNewswire) May 9, 2018
Bristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for Multiple Programs Targeting Immuno-Suppressive Factors in the Tumor Microenvironment: PRINCETON, N.J. & OSAKA, Japan–(BUSINESS WIRE)–$BMY–Bristol-Myers Squibb Granted Exclusive… https://t.co/tDraaRo0Yy pic.twitter.com/FZjSnGbDS1
— Business Wire-Health (@BW_Health) December 13, 2017
Bristol-Myers Squibb and Otsuka Pharmaceutical have reached a global settlement with plaintiffs in multidistrict litigation over side effects of their antipsychotic drug Abilify. https://t.co/Cxi3FktGho pic.twitter.com/pNGBz0wMFy
— Law360 (@Law360) February 26, 2019
Bristol-Myers Squibb, Daiichi Sankyo to Jointly Test Opdivo/DS-8201 Combo in HER2+… https://t.co/cnBZiI9qa3 pic.twitter.com/M95ccszHnv
— Immuno-Oncology News (@immunooncnews) September 5, 2017
Bristol-Myers Squibb starts research collaboration with Eisai – https://t.co/iKI2PJKO1q pic.twitter.com/m5oXPiRSCQ
— GMPnews.Net (@GMPnewsNet) December 17, 2018
https://twitter.com/UMCGlobalSafety/status/1180090377161908224
8-25-2020: Starting 4 months from now, Lilly's LY-CoV555, Regeneron's REGN-COV2, AstraZeneca's AZD7442, or Takeda/Behring/Octapharma might work for early COVID-19, be expensive, be vulnerable to mutations, and be in short supply:https://t.co/s29UYtb9o3https://t.co/ijHm26afc3
— Ronald M. Chavin (@rmchavin) August 25, 2020
Adimab broadens R&D deals with Novartis, Regeneron, Takedahttps://t.co/9gF1SqcuEq#R&D #novartis #regeneron #takeda #health #healthcare #pharmaceutical #digitalhealth #vitalyhealth
— Vitaly Health (@HealthVitaly) May 19, 2019
Adimab broadens R&D deals with Novartis, Regeneron, Takeda https://t.co/PLAwHC7tjz career medical device pic.twitter.com/cbGNbtODv1
— ThinKeen Global (@thinkeenglobal) May 8, 2019
Takeda and Regeneron continue to tap into Adimab’s capabilities https://t.co/lIicDWO57S pic.twitter.com/bUbVGC5pmH
— JackLeckerman (@JackLeckerman) May 13, 2019
“Regeneron (REGN) Reports Approval of DUPIXENT in Japan for Treatment of Atopic Dermatitis” https://t.co/kUdtuobA6v pic.twitter.com/2YRe5IDgEO
— Juan C Ivancevich MD (@Aller_MD) January 22, 2018
13 co's working on Coronavirus treatments/vaccines. Gilead's remdesivir is in late stage testing, GlaxoSmithKline is collaborating with Britain, U of Queensland. See also, Heat Biologics, Inovio, Johnson & Johnson, Moderna, Regeneron, Sanofi, Takeda, more. https://t.co/NyT4jixMES
— Dori Smith (@Dori_TalkNation) March 17, 2020
Biopharma's ever-evolving #COVID19 response, distilled:
Gilead, AbbVie, Pfizer looking at antivirals
J&J, Sanofi, and Moderna on vaccines
Regeneron, Eli Lilly, and Vir on antibodies
Takeda and Emergent on plasma therapyhttps://t.co/8S4Ucbc6ef— Andrew Dunn (@AndrewE_Dunn) March 13, 2020
Switzerland スイス Vol.2（pharmaceutical corporations 製薬会社）
All the below links and tweets are in English.
取り急ぎ以下貼っておきます。
Switzerland Vol.5 (pharmaceutical corporations: Novartis)
Switzerland Vol.6 (pharmaceutical corporations: Roche)
Switzerland Vol.7 (pharmaceutical corporations: Lonza, Actelion, Ferring Pharmaceuticals)
ツイッター検索で 上記5製薬会社各社名 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの
Last, reminding folks that novel pancoronavirus inhibitors are being developed by other big pharmas (Novartis, Takeda, Gilead, etc), who are moving very quickly: https://t.co/dn5JUpLXUy
— Lisa Jarvis (@lisamjarvis) September 17, 2020
Takeda just made a huge investment in cell therapy programs – a new R&D cell therapy manufacturing GMP facility in Boston. To cover 5 collab programs – Yamanaka, Rezvani, Sadelain, Noile-Immune Bio, GammaDelta Tx https://t.co/PNs2SXMubD Reminds me Novartis in the past…
— Alexey Bersenev (@cells_nnm) September 15, 2020
Global Candida Infections Drugs Market Industry Share, Size And Movements By Growth Status, Trend Analysis To 2020 – 2027 | Leading Players-Abbott, Pfizer Inc., Novartis AG, Merck & Co., Inc, Sanofi, Bayer AG, Astellas Pharma Inc., GlaxoSmithKline plchttps://t.co/d7povpUALz#new
— Pharma News (@pharminews) September 8, 2020
Boston Globe story yesterday on how small businesses in Central Square, #CambMA have been impacted by covid-19. https://t.co/ItouzHJizj. Biopharma companies in Central Sq incl Novartis, Takeda, Blueprint, Spero, Voyager, Beam, AbbVie, Fulcrum, Rheos, Neon/BioNtech, Intellia
— Pearl Freier (@PearlF) September 6, 2020
Fighting stigma — Alzheimer's Disease Consumption Market is Booming Worldwide 2020-2027 | Allergan, Eisai …: Alzheimer's Disease Consumption Market is Booming Worldwide 2020-2027 | Allergan, Eisai, Novartis, Daiichi Sankyo, Merz Pharma, Pfizer. https://t.co/AEaRUSbxKP
— STIGMABASE | EDU (@stigmabase) August 24, 2020
Otsuka beats back Novartis opposition with $15M purchase of smart pill developer Proteus https://t.co/bdi5MasNwb – was this the largest “de-valuation” of a #digitalhealth company ? Anyone have the stats ?
— Eugene Borukhovich (@HealthEugene) August 21, 2020
Discover the latest in the pharmaceutical legal landscape from legal experts who are shaping the landscape. Learn from, and liaise with, the likes of #Astellas Pharma, #AstraZeneca, #GSK, #Merck, #Novartis International AG, #Pfizer, #Teva, and many more! https://t.co/dqYm5O6NtJ pic.twitter.com/DJ93ECtTXO
— Pharma Regs – Informa Connect (@PharmaRegsIC) August 12, 2020
Sugar Coated Tablets Market Overview & Potential Growth Opportunities 2023| Key Players:Pfizer, Novartis, GSK & Eisai : Radiant Insights, Inc. https://t.co/0qhLWEgm0R pic.twitter.com/fAypRRPKo8
— ABNewswire (@ABNewswire) July 31, 2020
Global Drugs for Lipid Metabolism Disease Market 2020 Raises During Pandemic Phase 2021 | Merck, Novartis, Takeda Pharmaceutical – Best News Monitoring https://t.co/6mUdaMY12P
— Dr Jitesh Arora (@drjitesharora) July 29, 2020
Novartis announces new drug approved in Japan for patients with a specific mutation in advanced non-small cell lung cancer. #NSCLC #NovartisNews
— Novartis News (@NovartisNews) June 29, 2020
Japan's Takeda expects $200 million operating loss related to Novartis' Xiidra withdrawal https://t.co/XfZZGdOed5 pic.twitter.com/lH20KeVBns
— Reuters (@Reuters) June 29, 2020
Royalty Pharma's portfolio..AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta-all pay royalties to this company https://t.co/Y3l3KZvq1c
— MedicalQuack (@MedicalQuack) June 20, 2020
Guess who are stakeholders of the NICE guidelines for psychosis?
Astrazeneca UK Ltd, Pfizer, Sanofi, Roche, Bristol-Myers Squibb Pharmaceuticals, Eli Lilly, Janssen, Lundbeck, Novartis, Otsuka Pharmaceuticals etc.https://t.co/FQhUw8RHBz
— Nick (@NickWebb30) March 31, 2020
Well done BD, bioMérieux, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck (known as MSD outside the U.S. and Canada), Merck KGaA, Novartis, Pfizer, and Sanofi. https://t.co/f4ATL9azds
— Adam P Roberts (@GCAGATGCAATG) March 26, 2020
Japan approves Novartis' Zolgensma for spinal muscular atrophy in patients under two years old https://t.co/75M3RoPaHb #pharma pic.twitter.com/fBHwt0wNMU
— Pharmafocus (@Pharmafocus) March 19, 2020
https://twitter.com/Kamacintosh/status/1232044166886105089
https://twitter.com/RebeccaDRobbins/status/1222956083301322752
#Trending: Astellas Venture Management, Pitango Venture Capital and Novartis Institutes for BioMedical Research Lead TScan Series B – Business Wire#entrepreneur #venturecapital #vc #startups
Read More Here:https://t.co/OJ7yGj7EpW
— Chuck Russell (@iamChuckRussell) January 14, 2020
Astellas Venture Management Pitango Venture Capital and Novartis Institutes for BioMedical Research Lead TScan Series B: Total Series B Raise of $35 million TScan Therapeutics today announced the completion of its Series B raise with the inclusion of… https://t.co/ovyn92roLF
— Renal Cell Carcinoma (@Renal_Bio) January 9, 2020
Otsuka/Proteus, Novartis/Pear, Sanofi/Verily — pharmas & DtX partners are splitting up left and right. Should startups and investors be worried? @dave_muoio
digs in. https://t.co/vEUJmh5hrE via @MobiHealthNews— Jonah Comstock (@JonahComstock) December 16, 2019
There are examples of some big Pharma tech partnerships failing Novartis-Proteus. Otsuka-Proteus. Novartis-Pear. Sanofi now exits. But -while these experiments may not have paid off—there still seems to be appetite for innovation and AI. https://t.co/wBH4kvdTix
— Vasudev Bailey, PhD (@vasudevbailey) December 11, 2019
Biotech’s second year of red-hot takeovers is set for a strong finish with Astellas Pharma’s $3 billion buy and Novartis’s $6.8 billion deal for Medicines Co. https://t.co/H1o1vhp3vQ pic.twitter.com/TesYaDcEtn
— Bloomberg (@business) December 4, 2019
As mentioned earlier, Verily, Google's health care division, is also collaborating with Sanofi, Novartis, Otsuka and Pfizer to help them identify suitable patients for clinical drug trials. #digitalmarketing #optimization #growthhacking https://t.co/X1jXvUzYZu
— MRVSKY (@mrvskypro) December 1, 2019
Pharmaceutical Technology – #October’s top #news #stories https://t.co/xHDYOFwX6W #UCB #RA | #Novartis #Microsoft | #Sobi #Dova | #Sanofi US #manufacturing | #Alexion #Achillion | #Bavarian Nordic #GSK | #Daiichi #Astellas | #Ipsen #Blueprint | …
— GESDAT GmbH (@GESDAT) November 5, 2019
Immunosuppressants Market Impressive Growth 2019 | GlaxoSmithKline plc, Novartis AG, Sanofi, Bristol-Myers Squibb Company, Pfizer Inc., Astellas Pharma Inc., Zydus Cadila https://t.co/UgRU3aWvgK pic.twitter.com/zRdA3OAcP7
— ABNewswire (@ABNewswire) September 13, 2019
Anokion helped launch the Cambridge-based start-up it acquired today, Kanyos, back in 2015. Kanyos' early backers also included Versant Ventures, Astellas, and the venture arms of Novartis and Novo Nordisk. https://t.co/R6CzYpsmWn
— Kate Sheridan (@sheridan_kate) September 11, 2019
Google sister-company Verily is teaming with big #pharma companies such as Novartis, Sanofi, Otsuka and Pfizer on clinical trials with the goal to aggregate data across a variety of sources. Read more: https://t.co/nsC84fgcWY
— BrackenData (@BrackenData) July 13, 2019
Verily has formed alliances with Novartis, Sanofi, Otsuka, and Pfizer to work on clinical trials. So, what do they get out of the deal? https://t.co/QmgSYRsMhN
— STAT (@statnews) May 26, 2019
Verily announced a strategic collaboration deal with Novartis, Otsuka, Pfizer, Sanofi and six major health systems. https://t.co/HiKfv83vzM
— BioSpace (@biospace) May 21, 2019
The deals with Novartis, Otsuka, Pfizer and Sanofi will boost its ecosystem and “could help foster greater scientific discovery” as the pharma companies work on “next-generation research and development programs,” Verily said: https://t.co/h6tD7yJiaf
— FierceBiotech (@FierceBiotech) May 21, 2019
Adimab broadens R&D deals with Novartis, Regeneron, Takedahttps://t.co/9gF1SqcuEq#R&D #novartis #regeneron #takeda #health #healthcare #pharmaceutical #digitalhealth #vitalyhealth
— Vitaly Health (@HealthVitaly) May 19, 2019
Novartis' cancer treatment Kymriah gets Japan nod at cost of $305,800 https://t.co/dSZ1bpaPtM pic.twitter.com/pzy74432N2
— Reuters (@Reuters) May 15, 2019
Takeda selling Xiidra to Novartis: Takeda Pharmaceutical has entered into an agreement to sell Xiidra to Novartis for up to $5.3 billion. The sale will enable Takeda to focus on its key business areas of gastroenterology, rare diseases, plasma-derived… https://t.co/HnTfEdUjyK
— Keratomania | Keratoconus Advocacy Network (@Keratomania) May 9, 2019
Somewhere out there, Flemming Onskov is chuckling tonight —
Novartis buys Takeda’s new dry eye drug in $5.3B deal, hiring on 400 staffers in a blockbuster push on ophthalmology$NVShttps://t.co/Y9bP1tmV87— John Carroll (@JohnCendpts) May 8, 2019
$NVS $TAK – Novartis eyeing Takeda eye disease unit – Bloomberg https://t.co/E7Ko5Rzkxc
— Breaking News (@MarketCurrents) May 8, 2019
And another lobbyist fan of Buttieg, John Michael Gonzalez, is a DCCC bundler who reps PhRMA, Amgen, Astellas Pharma U.S., AstraZeneca, Celgene, Merck, and Novartis as well as Cigna, America’s Physician Groups and InnovaCare. https://t.co/UAnYI3VRyi https://t.co/7wAWNG5RpB
— Alex Kotch (@alexkotch) April 24, 2019
8 New drug structures revealed at #ACSOrlando….see them here !
Companies include: Amgen, Abbvie, Novartis, Takeda, Pfizerhttps://t.co/ZE68xbb5r7 pic.twitter.com/tYbPMJ45Gj— Organic Process Research & Development (@OPRD_ACS) April 5, 2019
We're excited to share that we have raised $31M from Novartis, Ping An Group, Chiesi Group, GuideWell and Otsuka to invest in Health Transformers #DigitalHealth #StartUpHealth #Moonshots https://t.co/ooWXzwiUrl
— StartUp Health (@startuphealth) September 25, 2018
Sun Pharma buys 14 drug brands from Novartis in Japan https://t.co/r8KEuqrOVT pic.twitter.com/l9MqFv1bwC
— Business Today (@BT_India) March 30, 2016
Sun Pharma agrees to buy 14 drug brands from Novartis in Japan https://t.co/hd6hsmpSKS pic.twitter.com/nq2uII5WfZ
— Hindustan Times (@htTweets) March 30, 2016
Novartis psoriasis drug approved in Japan http://t.co/THMqWEqEC3
— MarketWatch (@MarketWatch) December 26, 2014
https://twitter.com/pharmalot/status/562637508815900674
https://twitter.com/STForeignDesk/status/506366489046159360
https://twitter.com/DunyaNews/status/484281346127175680
Roche to look for approval of COVID-19, influenza test in Japan#roche #test #japan https://t.co/6xcMG2LcBO
— Breaking the News 24/7 (@Breaking24Seven) September 11, 2020
Roche Seeks Approval For Covid, Flu Combo Test In Japan – Nikkei https://t.co/2M41ejQXoG
— LiveSquawk (@LiveSquawk) September 11, 2020
The story behind the vitamin cartel of the 1990s, one of the most harmful and far-reaching cartels ever, provides a graphic example of the unscrupulous business ethics of the pharmaceutical industry.#vitamincartel #Roche #BASF #Takedahttps://t.co/qFRSiK0LYF
— Dr. Rath Foundation (@Dr_Rath_News) August 15, 2020
Chances of @Roche’s etrolizumab challenging @Takeda’s fast-growing Entyvio in the #ulcerativecolitis market look much diminished after top-line phase 3 results are revealed https://t.co/dNPqUYawVs
— pharmaphorum (@pharmaphorum) August 10, 2020
The Latest Info On Pharmaceutical Treatments And #Vaccines•#GileadSciences•#AbbVie•#Moderna•Johnson&Johnson•#EliLilly•#Pfizer•#GlaxoSmithKline•#VirBiotechnology•#Sanofi•Apeiron Biologics•#CureVac•#Dyadic•#Mesoblast•#Novavax•#Roche•#Takeda https://t.co/De0VjosMjf
— LebensKünstler (@GmmLhDBsc2heyst) March 20, 2020
https://twitter.com/IFPMA/status/1240674566214737920
The Daily Biotech Pulse: European Nod For Roche, Takeda … #biotech #bhivechat #bhivenectar #bhive https://t.co/W0wFVVxzqh
— BHIVE BioTech (@BHIVE_BioTek) September 7, 2019
Takeda v Roche: "Is it plausible? Is it true?" https://t.co/r69KeiEU09 via The IPkat pic.twitter.com/Dh88ug4qPT
— Zivko Mijatovic & Partners (@ZivkoMijatovicP) August 1, 2019
Xconomy – #Bio #Roundup: #Alzheimer’s Fail, #Drug #Price #Plan, #Gene #Therapies & #DRUG #DEVELOPMENTS https://t.co/QWpLu146cB #JnJ #Roche #Sunovion #Alexion #Takeda #Pfizer #Lilly …
— GESDAT GmbH (@GESDAT) February 1, 2019
At $74B, $BMS's $CELG deal is the largest ever outlay for a biotech takeout, topping Takeda-Shire. In terms of valuation, the deal is second only to Genentech’s '09 acquisition by Roche. Read more on today's pre #JPM2019 mega-deal in @BioCentury Extra: https://t.co/nC6wKWZxUW pic.twitter.com/EULYhKBfic
— BioCentury (@BioCentury) January 3, 2019
Japan approves Roche's entrectinib in tissue-agnostic indication, Daiichi's AML therapy quizartinib, Alnylam's Onpattro and Alexion's Ultomiris $ROG $ALNY $ALXN https://t.co/TON7QXZX5d
— BioCentury (@BioCentury) June 18, 2019
BioCentury's Sept. 12 clinical roundup includes Celgene plans for regulatory submission in AML on Phase III meet; plus clinical updates from Roche, Tocagen, Adverum, Daiichi Sankyo and more $ROG $TOCA $ADVM $APPL https://t.co/MEXuxEYsAm
— BioCentury (@BioCentury) September 13, 2019
BioCentury's March 26 product development roundup includes approval of Pear's digital therapeutic for insomnia; plus Medimetriks-Otsuka, Merck KGaA, Jazz, Roche, EpiVax $JAZZ https://t.co/W7EATOXux0
— BioCentury (@BioCentury) March 27, 2020
https://twitter.com/RebeccaDRobbins/status/1222956083301322752
Oncolytic Virus Market Analysis and Reviews 2019 to 2025 | Merck, Otsuka Pharmaceutical Co, Pfizer, Roche, Cold Genesys, Genelux https://t.co/5MnJLhS6t2 pic.twitter.com/4THnWUqxql
— Science Examiner (@ScienceExaminer) October 7, 2019
AstraZeneca and Daiichi Sankyo to jointly develop cancer drug https://t.co/bISxvzKf94 pic.twitter.com/BYUzQaMd4B
— Reuters Business (@ReutersBiz) March 29, 2019
AstraZeneca Plc will pay up to $6.9 billion (5.2 billion pounds) to work with Daiichi Sankyo Co Ltd on a hotly-tipped experimental treatment for breast cancer, in a direct challenge to the world's biggest cancer drug maker Roche.
"AstraZeneca pays up to… https://t.co/4TTdJW5BNp
— kristoferkawas (@kristoferkawas) March 29, 2019
Interested in #immunotherapy & #immunohistochemistry?
Check out DDNews’ e-news w/ stories from MorphoSys, Roche, Daiichi Sankyo & UCSD
PLUS resources from sponsor Cell Signaling Technologyhttps://t.co/ueiomZAZMq#immunooncology #diagnostics #antibodies #CellTherapy #microRNA pic.twitter.com/IwTXzDT7s3
— DDNews Online (@DDNewsOnline) February 15, 2019
UK biotech Celleron Therapeutics has bought a licence to develop, manufacture and market emactuzumab, an unwanted drug from Roche’s pipeline that could be used in a rare tendon sheath cancer already targeted by Daiichi Sankyo https://t.co/Olet72u08f
— pharmaphorum (@pharmaphorum) August 12, 2020
Lung Cancer Therapeutics Market Research, Recent Trends and Growth Forecast 2027 | #Roche, #Eli Lilly and company, #Pfizer, #Agennix AG and #Snaofi-Aventis, #Daiichi Sankyo, #AstraZeneca, #GlaxoSmithKlinehttps://t.co/kQhkhOLn48
— A2ZMarketResearch (@A2ZResearch) July 31, 2020
Major Players in the #Musculoskeletal #Disorders #Drugs #Market are F. Hoffmann-La Roche Ltd; GlaxosmithKline Plc; Pfizer Inc; Abbott Laboratories Inc; Daiichi Sankyo Company
Read More @ https://t.co/zAg48gjJ1d#marketresearch #research #TBRC pic.twitter.com/CgSHsx04l1
— Sreeramakrishna TBRC (@sreeramtbrc) June 5, 2020
ASCO: In stomach cancer, AstraZeneca and Daiichi's Enhertu goes where Roche's Kadcyla couldn't https://t.co/QH4teeefRW
— EIPG (@EIPGeu) May 30, 2020
https://twitter.com/HAccordingly/status/1221321860236955649
Eisai is creating a new US corporate, R&D HQ in Roche’s old Nutley, NJ campushttps://t.co/OcqukRYGP5
— John Carroll (@JohnCendpts) August 11, 2020
Merck, Eisai's Keytruda-Lenvima combo stonewalled in liver cancer after Roche's first-in-class green light https://t.co/fCgfHt2mPc
— FiercePharma (@FiercePharma) July 8, 2020
https://twitter.com/ResearchNews_24/status/1154008113730576384
Lonza Reaches Milestone with Takeda – https://t.co/uYf0bWpOmB pic.twitter.com/oqJ37NniGt
— GMPnews.Net (@GMPnewsNet) January 14, 2019
Lonza, Takeda reach regulatory milestone in oncology tie-up https://t.co/chKQ0JKFRx
— Cleanroom Supplies (@Cleanroomsupply) January 18, 2019
https://twitter.com/JanssenAP/status/1177073498864279552
Sphingosine 1-Phosphate Receptor 1 Market to See Major Growth by 2025 | Actelion, Arena Pharmaceuticals, Astellas Pharma,… https://t.co/JV6hlVG9tZ >>> https://t.co/HTA6IsoHwv #strategy #competitiveintelligence #marketing #pharma #healthcare #biotech #pharmaceutical #CI pic.twitter.com/odm4opMknO
— Dr Timos Papagatsias (@_timos_) February 19, 2019
Global Prostate Cancer Therapeutics Market 2026 – Sanofi, Takeda, Johnson & Johnson, Teva Pharmaceuticals, Pfizer, Ferring Pharmaceuticals, Ipsenhttps://t.co/MqR8Y7rxmL#news #pharma #pharmiweb
— Pharma News (@pharminews) June 23, 2020
Global Prostate Cancer Therapeutics Market In-Depth Research on industry & Emerging Growth Factors || Major Players are Tolmar INC, Ferring Pharmaceuticals, Takeda pharmaceutical co. Ltd., Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Pfizer Inchttps://t.co/fFjHRbxhKX#new
— Pharma News (@pharminews) March 23, 2020
Increase in research & development in oncology therapeutic area is Driving The Global Prostate Cancer Therapeutics Market with Higher CAGR | Major Players are Tolmar INC, Ferring Pharmaceuticals, Takeda pharmaceutical co. Ltd., Teva Pharmaceutical… https://t.co/fSa9mrn6wy pic.twitter.com/asxRZ4JUMe
— Oncology Board (@mb_Oncology) September 21, 2019
Recent articles about Japan 日本関連英文記事 Vol.2
All the below tweets are in English.
Japan's economy minister instructed by new PM to take steps without hesitation https://t.co/SiCJ1ZTnFU pic.twitter.com/lFsQdM8851
— Reuters (@Reuters) September 17, 2020
Japan's reappointed finance minister Aso says will prod regional banks to pursue reforms https://t.co/WAZp0v2BNV pic.twitter.com/4WuhopXYo3
— Reuters (@Reuters) September 17, 2020
BOJ to hold fire, signal resolve to work closely with Suga's new cabinet https://t.co/yqw5rAjbSZ pic.twitter.com/dTr8OriSFV
— Reuters (@Reuters) September 17, 2020
Japan's longest-serving prime minister Shinzo Abe left office amid applause before his longtime aide Yoshihide Suga was voted prime minister by parliament https://t.co/hKCJX4sWIZ pic.twitter.com/VYrTnrLJJp
— Reuters (@Reuters) September 16, 2020
Japan’s new Prime Minister Yoshihide Suga said he would stick with his former boss’ 'Abenomics' growth policies while pushing reforms https://t.co/PFUWnSF9bC pic.twitter.com/4tlbtLOFFM
— Reuters (@Reuters) September 16, 2020
From @Breakingviews: Japan has a new prime minister after nearly eight years. Yoshihide Suga, the tight-lipped technocrat, will need to shed some of his stern demeanor to lead the country out of recession, says @petesweeneypro pic.twitter.com/eWji7cC9sE
— Reuters (@Reuters) September 16, 2020
Telefonica partners with Japan's Rakuten to develop open 5G network https://t.co/FQtFzQyIMf pic.twitter.com/BNsFRXUpkh
— Reuters (@Reuters) September 16, 2020
China says it hopes Japan will not develop official ties with Taiwan https://t.co/S8aWZPP07W pic.twitter.com/IxK1g8HGVh
— Reuters (@Reuters) September 16, 2020
Japan’s Yoshihide Suga was voted prime minister by parliament to become the country’s first new leader in nearly eight years, appointing a new cabinet that kept about half of the familiar faces from predecessor Shinzo Abe’s lineup https://t.co/e9YG3w6TL6
— Reuters (@Reuters) September 16, 2020
Japan's exports extend double-digit declines as pandemic hits demand https://t.co/e3kNHS0rOJ pic.twitter.com/wJKcX7OBE1
— Reuters (@Reuters) September 16, 2020
Japan defence minister Kono to become internal affairs min in new cabinet: Kyodo https://t.co/PH4IqpQmUo pic.twitter.com/C75zhyYPEc
— Reuters (@Reuters) September 15, 2020
After sweeping party poll, Japan's Suga faces tricky call on snap election https://t.co/hXKdA0zFZb pic.twitter.com/yYvm4vUcQP
— Reuters (@Reuters) September 15, 2020
Japan's Aso says should consider early dissolution of parliament https://t.co/PI5GGsIn5T pic.twitter.com/0UQwnnEols
— Reuters (@Reuters) September 15, 2020
Japan's new leadership agenda could make jobs a bigger BOJ priority https://t.co/jfL67MCYVv pic.twitter.com/DjgE1y38Dv
— Reuters (@Reuters) September 15, 2020
Japan ruling party head Suga preparing cabinet, continuity in foreground https://t.co/4WcznGiSY5 pic.twitter.com/2FJqlXeXJ1
— Reuters (@Reuters) September 15, 2020
Japan health minister Kato likely to replace Suga as chief cabinet secretary: Nippon TV https://t.co/ErdsJudoE6 pic.twitter.com/LDsrJGTs6n
— Reuters (@Reuters) September 15, 2020
From @Breakingviews: Nvidia will buy UK-based chip designer Arm from Japan’s SoftBank Group and its growth will depend on winning over many of Arm’s customers like Intel, which compete with Nvidia, as well as anti-trust regulators around the world, @LiamWardProud says pic.twitter.com/kmcEjAooNu
— Reuters (@Reuters) September 15, 2020
United Airlines to close Japan's Narita hub, affecting 270 jobs: NHK https://t.co/OqmpLBQHfu pic.twitter.com/x2n3OOKtWU
— Reuters (@Reuters) September 14, 2020
Japan's Suga wins ruling party leadership race to replace Abe https://t.co/zs7oL16itL pic.twitter.com/zsSHbVTY38
— Reuters (@Reuters) September 14, 2020
Japan’s Yoshihide Suga wins ruling party leadership election, paving the way for him to become prime minister in a parliamentary vote this week https://t.co/YRwm9K9Int pic.twitter.com/3v3Mf1JIOr
— Reuters (@Reuters) September 14, 2020
Japan's next prime minister as a boy: good in sports, 'stiff' as actor https://t.co/92zlCQfyYQ pic.twitter.com/3UKmjxhTkO
— Reuters (@Reuters) September 14, 2020
Factbox: Japan next premier's hometown: demographic challenges by the numbers https://t.co/1QTxKQCVxG pic.twitter.com/uYzx0b55Te
— Reuters (@Reuters) September 14, 2020
Japan's Suga says no limit to bonds government can issue https://t.co/3UiYqHO5yH pic.twitter.com/pMLXlXn8Aa
— Reuters (@Reuters) September 13, 2020
Japan's Suga says no limit to bonds government can issue https://t.co/47gMZ8iSS1 pic.twitter.com/1Z6Zr4GW3H
— Reuters (@Reuters) September 13, 2020
Osaka 'a Jesse Owens of Japan' for racial injustice stand https://t.co/imj7cYQq6T pic.twitter.com/sz0sVBx8j1
— Reuters (@Reuters) September 12, 2020
Hip hop hooray for Japan's next PM with hometown T-shirt shout-out https://t.co/AoHablSyRd pic.twitter.com/PDxTZiwS7N
— Reuters (@Reuters) September 12, 2020
Japan's Suga, likely next PM, says ready to top up payouts to ease COVID-19 pain https://t.co/3I5JpaJRM1 pic.twitter.com/271DkXf312
— Reuters (@Reuters) September 12, 2020
Japan's Suga seeks solid communications with Asian neighbors https://t.co/dTL3DCFEJK pic.twitter.com/1iEUL3WkjB
— Reuters (@Reuters) September 12, 2020
Tiffany gets regulatory nod from Japan, Mexico for troubled LVMH deal https://t.co/VqNr9haIIm pic.twitter.com/Dn4jrGvVPh
— Reuters (@Reuters) September 11, 2020
Abe plan for land-attack counterpunch could mark major military shift for Japan https://t.co/N3f7XG0xhq pic.twitter.com/CFgEMjmg4A
— Reuters (@Reuters) September 11, 2020
UK and Japan strike Britain's first post-Brexit trade deal https://t.co/KTn04NK77g pic.twitter.com/BxaqsrdWbx
— Reuters (@Reuters) September 11, 2020
Japan's new government should focus on response to coronavirus, digitalization: Reuters poll https://t.co/1rmBToSQ86 pic.twitter.com/2PacSUBneb
— Reuters (@Reuters) September 11, 2020
Japan foreign minister says aims to reach broad agreement on UK trade deal Friday https://t.co/lIXpIorFrb pic.twitter.com/BvA9E7BOZl
— Reuters (@Reuters) September 11, 2020
Japan firms plan to cut capex by 6.8% this fiscal year: survey https://t.co/cjgobzhKJO pic.twitter.com/yQzvX3gUgg
— Reuters (@Reuters) September 11, 2020
Japan's Suga: Will have to call for sales tax hike in future https://t.co/4P8FLYxHCw pic.twitter.com/SRlShwBXgo
— Reuters (@Reuters) September 10, 2020
Stuck at home for weeks while Japan was under a state of emergency due to the coronavirus, renowned Japanese Bunraku puppet master Kanjuro Kiritake, all his performances canceled for months, was stricken with deep anxiety https://t.co/ITent24Oip
— Reuters (@Reuters) September 10, 2020
Yoshihide Suga, on course to become Japan’s next prime minister, said he would maintain incumbent premier Shinzo Abe’s policy prioritizing economic growth over efforts to fix the country’s tattered finances https://t.co/n0731rDKOc
— Reuters (@Reuters) September 9, 2020
Exclusive: Japan ruling coalition partner Komeito indicates it does not want snap election https://t.co/oEcSPCorwu pic.twitter.com/fuompQDij9
— Reuters (@Reuters) September 9, 2020
Japan's households, firms keep hoarding cash at record pace as COVID-19 strains broaden https://t.co/rLbJKNkW0A pic.twitter.com/pLs5P2Re3o
— Reuters (@Reuters) September 9, 2020
Japan's Suga in pole position for PM as debate kicks off https://t.co/AWXlIX2ibM pic.twitter.com/H5UMOlUlFr
— Reuters (@Reuters) September 9, 2020
Japan's Suga says important to cover fertility treatment by national insurance https://t.co/8xeoz2tlgy pic.twitter.com/8XDyhPHQJa
— Reuters (@Reuters) September 9, 2020
Japan’s economy shrank by over 28% in the second quarter as the global crisis had businesses struggling more than initially thought, underscoring the daunting task the new prime minister faces in averting a steeper recession https://t.co/WGdKT6Sbrd pic.twitter.com/fi2eOCJQ2X
— Reuters (@Reuters) September 8, 2020
Japan's Chief Cabinet Secretary Yoshihide Suga, a frontrunner to succeed Prime Minister Shinzo Abe, could call a snap election to solidify his political grip if he becomes the country's next premier https://t.co/mN5FBhmnnE pic.twitter.com/pH5vQRfS81
— Reuters (@Reuters) September 8, 2020
Tokyo 2020 Olympics organisers have not extended sponsors’ contracts set to expire at the end of the year, sources said, leaving some questioning whether to continue after COVID-19 forced a delay of the world’s largest sporting event https://t.co/e51BZ3IRaD
— Reuters (@Reuters) September 8, 2020
Factbox: Continuity and reforms: Japan PM hopeful Suga's key policies https://t.co/Gr20nDT77C pic.twitter.com/NXxZB5a5tP
— Reuters (@Reuters) September 8, 2020
Japan defence chief Kono expects to be prime minister one day, but backs Suga to succeed Abe https://t.co/DD2zcP0akQ pic.twitter.com/UtWRxXKs1T
— Reuters (@Reuters) September 3, 2020
Japan LDP heavyweight Kishida: Frank discussions needed with U.S. over defence burden https://t.co/7Hq6jQl89v pic.twitter.com/bgteKbqja5
— Reuters (@Reuters) September 2, 2020
Japan former foreign minister Kishida announces candidacy to succeed PM Abe https://t.co/KAJ37IIfMb pic.twitter.com/qMr56YBcHi
— Reuters (@Reuters) September 1, 2020
Japan's PM candidate Kishida cautious about cutting sales tax https://t.co/c2rpGAR3j5 pic.twitter.com/eQ4ijGJ9LI
— Reuters (@Reuters) August 31, 2020
Japan Defence Minister Kono says still undecided on run for ruling party leadership https://t.co/RIOCsS4eR8 pic.twitter.com/mL7SYNzqWs
— Reuters (@Reuters) September 1, 2020
Ex-defence minister Ishiba is people's choice for next Japan PM: polls https://t.co/vz2wwRC27L pic.twitter.com/FDUz78EpgK
— Reuters (@Reuters) August 31, 2020
Japan's Koizumi won't seek to succeed Abe as PM, would back Kono – NHK https://t.co/qkqUEYeUkN pic.twitter.com/sD38jEwhIV
— Reuters (@Reuters) August 30, 2020
Japan’s Sumitomo Corp. exits U.S. shale gas industry. via @Reuters https://t.co/wowqaMYt5d
— IEEFA_AsiaPacific (@IEEFA_AsiaPac) September 10, 2020
BREAKING: Yoshihide Suga has been formally elected Japan’s prime minister in a parliamentary vote. Suga was long the right-hand man to his predecessor, Shinzo Abe, who was Japan’s longest-serving prime minister. https://t.co/p6Ux2TPe3w
— The Associated Press (@AP) September 16, 2020
Yoshihide Suga has been elected as the new head of Japan’s ruling party, virtually guaranteeing him parliamentary election as the country’s next prime minister. https://t.co/Qjb7UPKAPp
— The Associated Press (@AP) September 14, 2020
Japanese prime minister hopeful Yoshihide Suga says he lacks the kind of diplomatic skills that outgoing leader Shinzo Abe has, including Abe's personal friendship with President Trump, and that he will need his assistance if he assumes the top job. https://t.co/Z176gjbjIN
— The Associated Press (@AP) September 12, 2020
https://twitter.com/AFP/status/1306237603637874688
#UPDATES Japan's parliament elects Yoshihide Suga prime minister, with the former chief cabinet secretary expected to stick closely to policies championed by Shinzo Abe during his record-breaking tenure https://t.co/BsfvhxSd6V pic.twitter.com/YXORmDXKA9
— AFP news agency (@AFP) September 16, 2020
Japan's parliament votes today for the country's next prime minister, with powerful cabinet secretary Yoshihide Suga all but assured the top jobhttps://t.co/8wZhfDupzw pic.twitter.com/ULPxi84Riw
— AFP news agency (@AFP) September 16, 2020
VIDEO: Japan's chief cabinet secretary Yoshihide Suga pledges a continuation of Shinzo Abe's policies as he is elected as the ruling party's new leader, making him all but certain to become the country's next prime minister pic.twitter.com/Utn5ZAoruf
— AFP news agency (@AFP) September 15, 2020
VIDEO: Japan ruling party elects Yoshihide Suga as PM successor.
The vote makes Suga all but certain to replace Shinzo Abe as the country's next prime minister pic.twitter.com/l9dfDW0Wee
— AFP news agency (@AFP) September 14, 2020
Japan's ruling party votes today for its next leader, with top government adviser Yoshihide Suga all but certain to win and replace Shinzo Abe as the country's new prime ministerhttps://t.co/yXRA6YPdmV pic.twitter.com/wRzMpvdWNV
— AFP news agency (@AFP) September 14, 2020
Japan's Yoshihide Suga to formally take up PM job, announce 'continuity' cabinet https://t.co/lCq86q9598 pic.twitter.com/8TVMcOF1tS
— FRANCE 24 (@FRANCE24) September 16, 2020
Japan's Yoshihide Suga wins leadership race to succeed outgoing PM Shinzo Abe https://t.co/XJCoFr5ful pic.twitter.com/wS6Dbftjiu
— FRANCE 24 (@FRANCE24) September 14, 2020
https://twitter.com/France24_fr/status/1305432334355902464
https://twitter.com/France24_en/status/1305441224132898817
https://twitter.com/i_montaigneEN/status/1305157795155714049
Concerns about the US’ readiness and ability to fulfill its security commitments have led Japan to enact security reforms to enhance its value as an ally while moving toward a more autonomous defense posture to prepare for the worst-case scenario.
➡️ https://t.co/CPn7pN2wRD pic.twitter.com/9aIPHUl32E
— IFRI (@IFRI_) July 24, 2020
In Japan, language is an integral part of a vertical society in which submission is a virtue. Japanese has different words for addressing a superior, a colleague or a sibling, which signal their place in society.https://t.co/1huvL32KBl
— Le Monde diplomatique in English (@LMdiplo) September 13, 2020
Years after the tsunami that swept northeast Japan, towns are being rebuilt. But will their inhabitants return, and should they? Fukushima’s toxic legacy will last for decades.
(September: the longer view.)https://t.co/MD2pzQ0djt
— Le Monde diplomatique in English (@LMdiplo) September 13, 2020
Yoshihide Suga won Japan's ruling party leadership race, virtually guaranteed to become the country's next prime minister. https://t.co/XLmF1dJ6ss
— DW News (@dwnews) September 14, 2020
Recent articles about Japan (mainly on new cabinet) 主に新内閣発足についての日本関連英文記事 Vol.1
All the below tweets are in English.
日本関連ツイートを拾うことは通常どおり特にしない予定でしたが、Reuters社を中心に以前よりは数が増えている感触があるので、前回投稿分以降の日付のものを中心にざぁっとですが拾ってみました。３回に分けて投稿します。
While I have not intended to collect news articles mainly on Japan’s new cabinet, I have come to confirm that there are more articles – mainly by Reuters – related to such issues than before as I have thought. That is why I collected roughly and posted here mainly tweets after the last post (Sep 8). This is the first of the three posts this time.
Hitachi to pull plug on north Wales nuclear power station https://t.co/9UiBT8ivbX
— The Guardian (@guardian) September 15, 2020
A Japan trade deal is little consolation if Britain is locked out of the EU https://t.co/VFXzXABLgg
— The Guardian (@guardian) September 13, 2020
Japan trade deal is small beer – but a welcome distraction https://t.co/PYes0nZkXr
— The Guardian (@guardian) September 11, 2020
UK government hails 'historic' trade deal with Japan https://t.co/tCu1vE1VHZ
— The Guardian (@guardian) September 11, 2020
Tokyo Olympics must be held at 'any cost', says Japanese minister https://t.co/s3iKj7upPC
— The Guardian (@guardian) September 8, 2020
Yoshihide Suga emerging as favourite to become Japan's prime minister https://t.co/kvdxwSftOD
— The Guardian (@guardian) September 1, 2020
#FPCJ #japannews @guardian
Yoshihide Suga to be Japan's prime minister after winning party vote https://t.co/NvynYefFBG— Foreign Press Center Japan/フォーリン・プレスセンター (@fpcjpn) September 15, 2020
#FPCJ #japannews @guardian
Yoshihide Suga: the farmer's son set to be Japan's next PM https://t.co/LNojbwYdMz— Foreign Press Center Japan/フォーリン・プレスセンター (@fpcjpn) September 14, 2020
Yoshihide Suga was elected Japan’s new prime minister in a parliamentary vote, following the resignation of Shinzo Abe https://t.co/3topdlCjap
— The Telegraph (@Telegraph) September 16, 2020
Who is Yoshihide Suga, the new Prime Minister of Japan? https://t.co/s885naHuXp
— The Independent (@Independent) September 16, 2020
Yoshihide Suga formally elected as Japan’s new prime minister https://t.co/3JhhviQCOW
— The Independent (@Independent) September 16, 2020
Yoshihide Suga: The unexpected rise of Japan’s new prime minister https://t.co/VbOcBegU78
— BBC News (World) (@BBCWorld) September 16, 2020
Yoshihide Suga elected Japan's new prime minster succeeding Shinzo Abe https://t.co/ifNL6ETIOn
— BBC News (World) (@BBCWorld) September 16, 2020
Yoshihide Suga: The strawberry farmer's son on track to be Japan's PM https://t.co/QrvbOikYnt
— BBC News (World) (@BBCWorld) September 14, 2020
#FPCJ #japannews @BBCWorld
BBC News – Yoshihide Suga: The strawberry farmer's son on track to be Japan's PM https://t.co/t8t07LBXBr— Foreign Press Center Japan/フォーリン・プレスセンター (@fpcjpn) September 15, 2020
Japan's new prime minister Yoshihide Suga promises to turn round economy after succeeding Shinzo Abe https://t.co/GR4b8Dk1tf
— SkyNews (@SkyNews) September 16, 2020
Yoshihide Suga is set to become Japan's new prime minister, following the resignation of Shinzo Abe https://t.co/iWjgw5zvB7
— SkyNews (@SkyNews) September 14, 2020
Each year, the Japanese drink enough ready-to-drink coffee to fill Tokyo’s new Olympic Stadium almost to the brim https://t.co/rz81kHc1J0
— The Economist (@TheEconomist) September 16, 2020
Japan's shrinking and ageing population is stoking the demise of rural railway lines https://t.co/pXlPOztwDu
— The Economist (@TheEconomist) September 16, 2020
Suga Yoshihide secured the support of Japan’s ruling Liberal Democratic Party by pledging continuity and stability at a time of crisis https://t.co/pPcvZVPBXe
— The Economist (@TheEconomist) September 15, 2020
Today on “The Intelligence”: Japan’s new prime minister, the state of the World Health Organisation and the great canine schism among Egypt’s clerics https://t.co/xDPKcE3gSE
— The Economist (@TheEconomist) September 15, 2020
If Japan's next prime minister succeeds, it will be thanks in large part to the groundwork laid by Abe Shinzo https://t.co/SALMLrrYPp
— The Economist (@TheEconomist) September 6, 2020
Many have cast Abe Shinzo's resignation as an admission of defeat. But Japan's outgoing prime minister has done a far better job than is commonly acknowledged. Our cover in Asia this week https://t.co/epAEDInipU pic.twitter.com/PnzNEhbBHR
— The Economist (@TheEconomist) September 3, 2020
“It says: ‘Please attack us’,” complains a campaigner against a proposed military base in Japan https://t.co/abFed4jNNm
— The Economist (@TheEconomist) August 15, 2020
#lockdown giving you itchy feet? Over on our #blog, Dr Sonia Favi discusses how in the Tokugawa era, #maps provided a 'virtual' means of exploring and domesticating the Japanese territory, even when physical travel wasn’t possible https://t.co/5Aw3iZidtC @TheJohnRylands @UoMSALC pic.twitter.com/VMnnLZANu8
— JRRI (@JRRIManchester) July 6, 2020
Yoshihide Suga is not your typical Japanese politician and yet the 71-year-old son of a strawberry farmer is about to become Japan's next prime minister | @ErykBagshaw https://t.co/YdxLk4wGgn
— The Sydney Morning Herald (@smh) September 14, 2020
Shinzo Abe's chief cabinet secretary Yoshihide Suga is set to become Japan's next prime minister after winning a mandate to continue his predecessor's domestic and foreign policy | @ErykBagshaw https://t.co/L5ehz7jTpb
— The Sydney Morning Herald (@smh) September 14, 2020
Yoshihide Suga, Japan's Chief Cabinet Secretary and a longtime loyal assistant of outgoing Prime Minister Shinzo Abe, has emerged as a favourite to succeed him in an upcoming internal party vote https://t.co/n1zNdzRRgy
— The Sydney Morning Herald (@smh) September 2, 2020
David Walton and Akimoto Daisuke: The decision by the Turnbull government in 2016 to select a French company to produce Australia’s next generation of submarines over Japan’s tender highlighted the limitations of networks and friendships.https://t.co/HRpQaOGhts
— The Lowy Institute (@LowyInstitute) September 4, 2020
"With Australia seeking ever-closer regional cooperation with Japan these days, it will be interesting to see whether the country’s investors will be unnerved by being caught in Australia’s trade row with China."@Greg__Earl writes for The Interpreter.https://t.co/NWqOT8rfcL
— The Lowy Institute (@LowyInstitute) August 31, 2020
Abe aimed to move mountains, setting Japan high goals for the future | Purnendra Jain https://t.co/vynrzxabC2
— The Lowy Institute (@LowyInstitute) August 30, 2020
With the Indo-Pacific increasingly a battleground for technological competition, it appears likely that US-China tensions will complicate Japan-ASEAN digital ties.
Elliot Silverberg and Patrick Madaj write for The Interpreter.https://t.co/lKvF8wR7P4
— The Lowy Institute (@LowyInstitute) August 16, 2020
"In a similar address to the Lowy Institute a year ago, @ScottMorrisonMP also praised India and Japan as countries with 'shared values' to Australia."@ConversationEDUhttps://t.co/iARwXSrBzA
— The Lowy Institute (@LowyInstitute) August 6, 2020
"In a commentary last year written for The Interpreter blog from Australia's Lowy Institute, Layton detailed just how far the Chinese flights stretch the JASDF, and how China has the resources to push Japan to limits it may not be able to reach."@cnnihttps://t.co/LnI3HSyOxu
— The Lowy Institute (@LowyInstitute) July 30, 2020
"An overwhelming 82 per cent of Australians said they expected Japan to act responsibly in the world. On the same question, the response regarding China was a dismal 23 per cent"
Nonresident Fellow @Rory_Medcalf on Lowy Institute Poll in @FinancialReviewhttps://t.co/0dAWDLfKCd
— The Lowy Institute (@LowyInstitute) July 13, 2020
Beyond Covid, the chance for a broader Australia-Japan relationship | Donna Weeks https://t.co/jWd4qbeuwC
— The Lowy Institute (@LowyInstitute) July 6, 2020
As China rises, does Australia, India, Japan, and the United States have any real prospect of rebalancing relationships in Asia?
Read the latest Lowy Institute Analysis on the Security Quadrilateral Dialogue by Dr Lavina Lee. https://t.co/3rHK0bjip3
— The Lowy Institute (@LowyInstitute) May 22, 2020
Japan: Article 9 conundrum rears its head again | David Walton https://t.co/g3erhFcktW
— The Lowy Institute (@LowyInstitute) February 24, 2020
Japan–South Korea tensions show little sign of easing | Kate Kalinova https://t.co/a5lWZFyghy
— The Lowy Institute (@LowyInstitute) February 17, 2020
#BREAKING Japanese Coastguard has reportedly made the decision to suspend its fulltime search for the 40 people still missing from the livestock ship. https://t.co/5kPFsNszQP pic.twitter.com/v3KPgjWKNA
— nzherald (@nzherald) September 10, 2020
#BREAKING Missing Kiwis: Japan to resume search for crew of livestock ship https://t.co/tAqQjJTgcc pic.twitter.com/YtKCeBkt2z
— nzherald (@nzherald) September 7, 2020
#BREAKING The second person rescued by Japanese coastguard has died. https://t.co/YrzrVGD9Sg pic.twitter.com/G3vTOgyyKc
— nzherald (@nzherald) September 4, 2020
#BREAKING They sent a distress signal at 4.45am NZT off the coast of Japan as the area was hit by a Typhoon. Now the ship has disappeared. https://t.co/UJUmRTrPFY pic.twitter.com/KGDrbXTWTJ
— nzherald (@nzherald) September 2, 2020
Japan's Parliament has elected Yoshihide Suga as prime minister, replacing long-serving leader Shinzo Abe with his right-hand man. https://t.co/i4yQL9llz4
— CBC News (@CBCNews) September 16, 2020
Yoshihide Suga has been elected as the new head of Japan's ruling party, virtually guaranteeing that he will become the country's next prime minister. https://t.co/rqR2DwTZGn
— CBC News (@CBCNews) September 14, 2020
One person in Japan is dead, and at least two are missing in South Korea after a powerful typhoon. https://t.co/f8sxEEjNOw
— CBC News (@CBCNews) September 8, 2020
U.S. authorities have arrested a former Green Beret and his son who are accused of using large boxes to help scurry Nissan chairman Carlos Ghosn out of Japan. https://t.co/UPxjNx3A05
— CBC News (@CBCNews) May 20, 2020
As the coronavirus spreads in Japan, the chief executive of the Tokyo Games said Friday he can't guarantee the postponed Olympics will be staged next year — even with the long delay. https://t.co/V6QqzigJwC
— CBC News (@CBCNews) April 10, 2020
Japan's prime minister says he will declare a state of emergency for seven prefectures, with Japan also launching its largest ever stimulus package. https://t.co/f6SWfrhyQg
— CBC News (@CBCNews) April 7, 2020
The streets of Tokyo remain busy as Japan adopts its own approach to preventing the spread of coronavirus, one that relies on tracing cases and requesting cooperation, not lockdowns. https://t.co/YKNNsYkV4N @sasapetricic
— CBC News (@CBCNews) April 4, 2020
Japan Olympic minister Seiko Hashimoto says the Tokyo Summer Games could be held later in 2020 due to fast-spreading COVID-19. https://t.co/8gEqMSG8cX
— CBC News (@CBCNews) March 3, 2020
Canadian quarantined in Japan with asymptomatic COVID-19 describes comforts during enforced stay. https://t.co/HfOuAh3Jhb pic.twitter.com/y70dRyVzIE
— CBC News (@CBCNews) February 27, 2020
Japan’s Yoshihide Suga poised to win party race, succeed Shinzo Abe as PM https://t.co/XHP4temuFe
— The Globe and Mail (@globeandmail) September 14, 2020
Japan, eyeing Olympics, lines up half-billion doses of COVID-19 vaccine https://t.co/N3ShUXL25O
— The Globe and Mail (@globeandmail) August 28, 2020
Japan says China has used coronavirus to expand territory, influence https://t.co/6vtuc3NY8T
— The Globe and Mail (@globeandmail) July 14, 2020
Japan to end Tokyo’s state of emergency, eyes massive new stimulus https://t.co/2xqo1lBlOs pic.twitter.com/SQsnCVxqFx
— The Globe and Mail (@globeandmail) May 25, 2020
Japan’s Shinzo Abe slammed over ‘stay home’ shutdown tweet https://t.co/ZpaFBQxGOg pic.twitter.com/93TI0ssMk1
— The Globe and Mail (@globeandmail) April 13, 2020
Nearly 40 feared dead as torrential rains continue to ravage southwest Japan https://t.co/6f7TjQpdH8 pic.twitter.com/DRfb2d0pvW
— The Globe and Mail (@globeandmail) July 6, 2020
Japan bracing for dangerously powerful Typhoon Haishen https://t.co/6iorZ3r31N
— The Globe and Mail (@globeandmail) September 4, 2020
Japan’s ruling party urges government to cancel Xi’s visit over new Hong Kong national security law https://t.co/CVKC12xKeB pic.twitter.com/g0Ybpfpp4g
— The Globe and Mail (@globeandmail) July 7, 2020
Japan ignored the usual rules but contained COVID-19. How did it work? https://t.co/dDDSjdHmbe
— National Post (@nationalpost) May 25, 2020
#Breaking: Olympic Games delayed one year after agreement reached with IOC and Japan PM. https://t.co/5AIrozWunM
— Toronto Star (@TorontoStar) March 24, 2020
France フランス Vol.6（pharmaceutical corporations 製薬会社）
All the below links and tweets are in English.
France Vol.15 (pharmaceutical corporations: Sanofi)
France Vol.16 (pharmaceutical corporations: Ipsen, Servier)
France Vol.17 (pharmaceutical corporations) Pierre Fabre, LFB Biotechnologies
ツイッター検索で 上記5製薬会社各社名 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの
1/ We were honored to host dinner this week to celebrate the closing of the @TakedaPharma acquisition of Shire and to welcome new USAIC Board Members: John Reed of @Sanofi Phillip Larsen of @Bayer and John Orloff of @AlexionPharma pic.twitter.com/W2TOzaJW6i
— USAIC (@USAIC) January 30, 2020
Through research we commissioned with @EIUPerspectives in the US, Japan and Europe, gaps have been uncovered in #cancer care for the aging, and the impact those gaps can have on healthcare systems. Find out more. #WhenCancerGrowsOld
— Sanofi (@sanofi) June 18, 2020
Through research with @TheEconomist in the U.S., Japan and Europe, we’ve uncovered gaps in #cancer care for the aging, and the impact those challenges can have on healthcare systems. Find out more about what we learned. #WhenCancerGrowsOld
— Sanofi (@sanofi) February 10, 2020
#DRG epidemiology report estimates more than 8.5 million diagnosed events of #RSV across the United States, Western Europe and Japan. Detailed report available now @DRGinsights #respiratorysyncytialvirus @sanofi https://t.co/qmI5DN8A8D
— DRG Epidemiology (@DRG_Epi) December 19, 2019
#DRG epidemiology report estimates more than 28 million #influenza events across the United States, Western Europe and Japan. Detailed report available now @DRGinsights #flu #ESCCongress #OurHeartIsInIt @sanofi https://t.co/b9ro3FzMDn
— DRG Epidemiology (@DRG_Epi) September 5, 2019
Currently, more than 190 million people suffer from #allergicrhinitis across the United States, Western Europe and Japan. Follow us for more updates on #DRG epidemiology data and forecast trends @DRGinsights @sanofi #WorldAllergyWeek https://t.co/UwFVqRvZUF
— DRG Epidemiology (@DRG_Epi) April 11, 2019
#DRG epidemiology report estimates nearly 30 million #influenza #flu events across the United States, Western Europe and Japan. @DRGinsights @sanofi https://t.co/aMX8ZwAEY0
— DRG Epidemiology (@DRG_Epi) August 22, 2018
J&J, Sanofi and more look to ink national COVID-19 vaccine supply pacts in EU, Japan: reports | @AstraZeneca @JNJ @gatesfoundation @melindagates @BillGates @UniofOxford @BARDA @Sanofi @Moderna @Pfizer @BioNTech @Curevac @GSK #covid19 #vaccine #Biotech https://t.co/cRcjPrjCy9
— Aspen Biosciences (@aspenbio) July 19, 2020
.@sanofi, the company that produces #Lantus, had already filed 74 patents for the drug in the US by 2018 – this is 1.5 times more than those in Europe, and almost triple than in Japan. pic.twitter.com/HBjUqpT2NU
— I-MAK (@IMAKglobal) November 8, 2019
How about a deal with @SangamoTx to better exploit protein homeostasis? Hematology is unpartnered @ScienceAtBMS @bmsnews @JoeSzustakowski.
Partners include @sanofi @NovartisScience @pfizer #takeda @GileadSciences @KitePharma @biogen$SGMO $BMY $PFE $NVS $SNY $GILD $BIIB https://t.co/tJzQPwFTgB— biotech 2050 (@Biotech2050) July 30, 2020
Also underlines the integrated approach championed by the @WHO i.e vaccine(s) alone are not the solution we have to pull together #diagnostics #communityengagement #vectorcontrol & is exactly why we are advocating for a @WorldDengueDay to be officially recognised @sanofi @Takeda https://t.co/NtOGRRTIar
— ISNTD (@ISNTD_Press) July 14, 2020
The key players in Non-Small Cell Lung Cancer #market include @Novartis, @Merck, @LillyPad, Hoffmann-La-@Roche, @Xcovery, @beyondspring26, @OSEIMMUNO, @sanofi, @Takeda, @abbvie and others.
For more detailed information visit: https://t.co/RWk90xqKhl#LungCancer #Cancer
— DelveInsight (@delve_insight) May 12, 2020
#Takeda’s #dengue shot, rival to #Sanofi's #Dengvaxia, hits the mark in massive phase 3 study https://t.co/GlYlVhHlSZ @FiercePharma @TakedaPharma @sanofi #vaccine #denguevirus
— Plexus Ventures (@PlexusVentures) January 30, 2019
Top pharma execs discuss and share #bestpractices of what they're doing to meet the challenges of COVID-19 @LillyPad @JNJNews @Roche @Sanofi @Takeda @IFPMA https://t.co/HngTgXpJtH
— Ogilvy Cambridge (@OgilvyCambridge) March 20, 2020
Open Targets is 5 and we would like to thank all our 355 staff from our partners @biogen @celgene @emblebi @GSK @takeda @sanofi @sangerinstitute + guest institutions for contributing & being part of such successful #precompetitive community. Here's to many more years to come! pic.twitter.com/eiVhWWVlXx
— Open Targets (@targetvalidate) June 21, 2019
Global Candida Infections Drugs Market Industry Share, Size And Movements By Growth Status, Trend Analysis To 2020 – 2027 | Leading Players-Abbott, Pfizer Inc., Novartis AG, Merck & Co., Inc, Sanofi, Bayer AG, Astellas Pharma Inc., GlaxoSmithKline plchttps://t.co/d7povpUALz#new
— Pharma News (@pharminews) September 8, 2020
Global Prostate Cancer Therapeutics Market Likely to Experience a Tremendous Growth in Near Future|| Johnson & Johnson Services, Inc., Astellas Pharma US, Inc., Sanofi, Ipsen Pharma, AbbVie Inc., Myovant Sciences Ltd., Bayer AGhttps://t.co/A1PMeJ5FeY#news #pharma #pharmiweb
— Pharma News (@pharminews) August 5, 2020
Pharmaceutical Technology – #October’s top #news #stories https://t.co/xHDYOFwX6W #UCB #RA | #Novartis #Microsoft | #Sobi #Dova | #Sanofi US #manufacturing | #Alexion #Achillion | #Bavarian Nordic #GSK | #Daiichi #Astellas | #Ipsen #Blueprint | …
— GESDAT GmbH (@GESDAT) November 5, 2019
FiercePharmaAsia—Sanofi's Japan cuts; Big Pharma CEOs' Chinese names; Astellas' ESMO win: https://t.co/RbSO8pbM2i #pharma #regulatory
— Pharma Regulatory (@EURegulatory) October 4, 2019
Immunosuppressants Market Impressive Growth 2019 | GlaxoSmithKline plc, Novartis AG, Sanofi, Bristol-Myers Squibb Company, Pfizer Inc., Astellas Pharma Inc., Zydus Cadila https://t.co/UgRU3aWvgK pic.twitter.com/zRdA3OAcP7
— ABNewswire (@ABNewswire) September 13, 2019
Global Urinary Drugs Market 2019 – Sanofi S.A., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Pfizer Inc., Bayer AG – Honest News 24
https://t.co/kHgcMcepxG— News SummedUp Kenya (@summedupkenya) July 17, 2019
It's Friday afternoon & time for #WeeklyRoundup Read the full article here: https://t.co/cJ5QMOVX5Z
Companies included: @Amgen @astellas @GSK@MSDInvents @Novartis @Pfizer_Ireland @sanofi @VertexPharma#MarketWatch #ThePMI19 pic.twitter.com/wB4do7MdZK— The PMI (Pharmaceutical Managers' Institute) (@PharmaMgrsInst) January 25, 2019
Big Pharma – Novartis, Pfizer, Sanofi, Otsuka – has decided to partner, rather than rival, with Alphabet's Verily to accelerate clinical trials. Here's a story I wrote about how Alphabet and Apple's clinical trial strategies differ https://t.co/fpW0j2H6hw https://t.co/6xM4gemxEW
— Hannah Kuchler (@hannahkuchler) May 21, 2019
The deals with Novartis, Otsuka, Pfizer and Sanofi will boost its ecosystem and “could help foster greater scientific discovery” as the pharma companies work on “next-generation research and development programs,” Verily said: https://t.co/h6tD7yJiaf
— FierceBiotech (@FierceBiotech) May 21, 2019
Novartis, Sanofi, Otsuka, and Pfizer will work with Alphabet’s #Verily on its #ProjectBaseline clinical research project https://t.co/kLtditGb31
— pharmaphorum (@pharmaphorum) May 22, 2019
As mentioned earlier, Verily, Google's health care division, is also collaborating with Sanofi, Novartis, Otsuka and Pfizer to help them identify suitable patients for clinical drug trials. #digitalmarketing #optimization #growthhacking https://t.co/X1jXvUzYZu
— MRVSKY (@mrvskypro) December 1, 2019
Amgen, Sanofi back a round for real-world evidence platform tech; Daiichi Sankyo’s pexidartinib secures speedy FDA review https://t.co/ic5dkzRo5Y
— Endpoints News (@endpts) February 5, 2019
Sanofi, Eisai join Lilly's SCOTUS bid to save Cialis from 'overly broad' patent claims https://t.co/2rBBlgNDID
— FiercePharma (@FiercePharma) July 9, 2019
https://t.co/sxLYhMpxvg – #Clinical #Catch–#up for June 10-14
https://t.co/XYnsCW41Fh #Sanofi #Lilly #ProventionBio #Eisai #Novartis #Genentech #Savara #BluebirdBio #Janssen #Hutchison #China #Meditech— GESDAT GmbH (@GESDAT) June 18, 2019
Global Prostate Cancer Therapeutics Market 2026 – Sanofi, Takeda, Johnson & Johnson, Teva Pharmaceuticals, Pfizer, Ferring Pharmaceuticals, Ipsenhttps://t.co/MqR8Y7rxmL#news #pharma #pharmiweb
— Pharma News (@pharminews) June 23, 2020
Medicine Fact's:
FEBUXOSTATFebuxostat was discovered by scientists at the Japanese pharmaceutical company Teijin in 1998. Teijin partnered the drug with TAP Pharmaceuticals in the US and Ipsen in Europe pic.twitter.com/iL1QiQyFES
— PharmahubNG (@pharmahub_NG) April 23, 2020
https://twitter.com/debasisdas/status/1191697468997505025
Cabometyx (cabozantinib; Exelixis/Ipsen/Takeda) Drug Overview & Product Profiles 2019 – https://t.co/8vPVgQlQhj https://t.co/QBZCpYtRTH
— Pharmacutical Daily (@PharmacDaily) June 26, 2019
#Ipsen joins @Arixbioscience’s growing pool of pharma partners #biotech #pharma #biopharma #biotechnology #VC #venturecapital #partnerships #EuroBiotech #France #UK #Fosun #Takeda #UCB $IPN $ARIX https://t.co/548ySCuIyC via @FierceBiotech
— Kara Jill Stancell (@kjilly) February 21, 2018
#Japanese #cancer Japanese regulators grant additional approval for the sale of Ipsen's rare cancer drug in Japan https://t.co/pmEsO6Mcov pic.twitter.com/MDv7v96yVV
— PharmaSources.com (@Pharmachina365) July 5, 2017
#efpbarca #medaffairs Ipsen, Eisai, and Astellas on why communicating data to external stakeholders is essential. Find out more here: https://t.co/6p0SXN2R3C pic.twitter.com/o4UdkJxsR8
— The Pharmaceutical Marketing Group (@PharmaMKTnet) October 24, 2018
https://twitter.com/Servier/status/1275363363812450305
https://twitter.com/Servier/status/1273889368801935360
https://twitter.com/Servier/status/1270038222144495616
https://twitter.com/ServierCDMO/status/987605428904366080
Onivyde Now Available in Japan: Servier/Yakult Nihon Servier and Yakult Honsha rolled out its cancer agent Onivyde (liposomal irinotecan) in Japan … https://t.co/h0pZ4komgH
— MEDWAVE (@medinfoa2z) June 2, 2020
Yakult to Promote Servier’s Anticancer Agent Liposomal Irinotecan in Japan Yakult Honsha and Nihon Servier, the Japan unit of the France-based Servier Group, have entered into… https://t.co/IuNVzWp4wK
— MEDWAVE (@medinfoa2z) October 9, 2019
https://twitter.com/conkers3/status/986959011038879744
Servier buys Shire’s oncology unit for $2.4B in the run-up to Takeda’s final buyout offer — if it makes one https://t.co/ie1viNsPi6 pic.twitter.com/VVjxrD1Jz3
— Endpoints News (@endpts) April 16, 2018
Shire's oncology exit weighs on potential Takeda bid: Shire plc is backing out of cancer drugs, announcing Monday the sale of its oncology business to French pharma Servier S.A.S. for $2.4 billion in cash. https://t.co/6TcuucnAtl
— cafepharma (@cafepharma) April 17, 2018
Shire sells cancer drugs to Servier for $2.4 billion as Takeda circles https://t.co/YexpoARs1k pic.twitter.com/yASy7SXm3Z
— Reuters (@Reuters) April 16, 2018
For those interested in the life sciences sector: Shire will be selling its oncology business to French company Servier for $2.4 billion — could this move prevent Japan's Takeda from making a takeover bid for Shire? https://t.co/fQJ2NzF4lA #lifesciences pic.twitter.com/In5rrSyKRn
— Chambers Associate (@ChambersAssoc) April 16, 2018
$SHPG announced today that they are willing to sell their oncology business to France's Servier SAS for about $2.4 billion, as it continues to discuss another possible $50 billion takeover by Japan's Takeda Pharmaceutical. https://t.co/UKVAuq8fLE pic.twitter.com/FG6cAk2Gle
— Stock Analyst (@USCheapStocks) April 16, 2018
#Japan @Takeda @Reuters @London @Japan @TakedaPharmaceutical @Servier #Cancer #DYK #AllThingsCancer #CancerMoonShot #EndCancer #FindACure #CancerTodayMag #JoinTheFight #CancerResearch https://t.co/lN4EPjg7gQ
Shire sells cancer drugs to #Servier as #Takeda circles— Ken Nitz (@knitz22) April 16, 2018
Three days until our West Coast Conference in L.A.! If you haven’t registered yet, there’s still time: https://t.co/Q2741YJGmW Huge thanks to our sponsors: @genentech @hsn @pfizerinc @pgbeauty @qvc @novartis, Eisai, @LLSusa & @Servier ✨ #bethebossovercancer #CACwestcoast pic.twitter.com/bSd4KXpTUy
— Cancer and Careers (@CancerAndCareer) October 23, 2019
Pharmaceutical Formulations for Asia from Japan
Pierre Fabre, a leading French manufacturer of pharmaceutical products and dermatological cosmetics, opened its Asia Innovation Center PFDC in Japan in 2014 and began formulations activities … https://t.co/6KNKghWWMd pic.twitter.com/Syp79UHJiW— HC_Tokyo (@nadoCb) February 3, 2018
Science and Technology 科学技術 Vol.9 ／ #Coronavirus #コロナウイルス Vol.11
All the below links and tweets are in English.
標記関連でまだ当サイトに貼っていなかったものにつき取り急ぎ以下貼っておきます。
Science and Technology Vol.39 (#telemedicine, agriculture, #ArtificialIntelligence, broadband)
Science and Technology Vol.38 (#coronavirus)
Science and Technology Vol.37 (#coronavirus, #bigdata, etc.)
Science and Technology Vol.36 (#robotics, #ArtificialIntelligence, #datascience)
Science and Technology Vol.35 (#coronavirus)
Science and Technology Vol.34 (#coronavirus, #telemedicine, #bigdata, etc.)
Science and Technology Vol.33 (telemedicine, climate change)
Science and Technology Vol.32
Science and Technology Vol.31
Science and Technology Vol.11 (artificial intelligence, robotics, etc.)
Science and Technology Vol.10 ノーベル賞 含む
Science and Technology Vol.9
Science and Technology Vol.8 ノーベル賞
Science and Technology Vol.7 イグノーベル賞 含む
Science and Technology Vol.6
Science and Technology Vol.5
Science and Technology Vol.4
Science and Technology Vol.3
Science and Technology Vol.2
Science and Technology Vol.1
ツイッター検索で出て来た broadband と日本に関連するツイート（The below are broadband-related Tweets which happened to come out of Twitter search on Sep 6. They must be just a part of all the posted Tweets as usual.）
The HAPS #HAWK30 is a next generation #Solar powered #UAS >>> @aerovironment and @SoftBank via @globaliqx >>> #Broadband #UAV #Drones #IoT #5G #Robotics #defstar5 #Aerospace >>> https://t.co/9dlZzzaKUz pic.twitter.com/qXF8hZ0cvU
— Mike Quindazzi ✨ (@MikeQuindazzi) December 19, 2019
City interview with Adrian Steckel, the boss of SoftBank-backed British satellite broadband firm OneWeb. He tells me the plans is to float in 24-36 months when it has launched all its satellites https://t.co/5bfuSmIj3c
— Jamie Nimmo (@JamieNimmo63) August 11, 2019
SoftBank is investing $125M in rural balloon broadband startup. pic.twitter.com/vMkawziQDX
— Digital Trends (@DigitalTrends) April 29, 2019
NTT Docomo’s bullet train mmWave 5G test speeds past 1Gbps https://t.co/LSWB46UTwp #Telecom #Networks #Telco #Cloud #Telecoms #Mobile #Wireless #IIoT #Broadband #IoT #EdgeComputing #5G @NTTDocomoNews @NTTDATAServices #japan
— Evan Kirstel #RemoteWork (@EvanKirstel) September 30, 2019
Docomo Offers 1Gbit/s Services to Train Going 283km/h Using 5G https://t.co/r2oDLyhnql via @Light_Reading #Telecom #Networks #Telco #Cloud #Telecoms #Mobile #Wireless #IIoT #Broadband #IoT #EdgeComputing #5G #japan @GlobalNTT @NTTDATAServices pic.twitter.com/DszjUnlXSP
— Evan Kirstel #RemoteWork (@EvanKirstel) October 1, 2019
Tokyo power company orchestrates 5G infrastructure sharing https://t.co/oJ1MCtD79Q #5G #APAC #BusinessModels #mmWave #Regulation #Research #SmartCities #Japan #Networks #Telecoms pic.twitter.com/bfdKQ9hQYT
— TelecomTV (@TelecomTV) March 19, 2019
KDDI is deploying https://t.co/TeRdCkxVRJ in Japan to tackle its huge MDU opportunity https://t.co/vxQywU8Ves #APAC #Broadband #Telecoms #Gfast #Fibre pic.twitter.com/WJnfp8FQYu
— TelecomTV (@TelecomTV) February 4, 2019
KDDI deploys Nokia gigabit https://t.co/vQJiRQTOpO solution to bring new services to its high-speed internet 'au Hikari' customers in Japan | Nokia https://t.co/RfBdVqtHiq #gfast #broadband
— Teresa Mastrangelo #broadband #smartcities (@broadbandtrends) February 4, 2019
KDDI takes conventional approach in land of new 5G architectures…https://t.co/34uaiPGsOM#wireless #5G #wifi #cellular #operators #spectrum #RAN #broadband #iot #rethinktechnology #iot @KDDI_Research @NTTDocomoNews @Rakuten @SoftBank @ericsson @nokia pic.twitter.com/cMpl3iWGNs
— Wireless Watch (@RethinkWireless) October 9, 2019
Gfast Brings High-Speed Broadband to KDDI MDU Customers https://t.co/S6XWP92djM
— Broadband World News (@BroadbandWN) February 5, 2019
BBWN Bites: Verizon, Spectrum Top Netflix Tier-One Speed Rankings
Also today, Boris's broadband goal gets no love in Parliament, Roku delivers for Apple fans, Tubi targets UK and kids, Rakuten TV brings freebie ad-supported service, Chile seeks tenders forhttps://t.co/UgMkqUnWTV— Broadband World News (@BroadbandWN) October 15, 2019
Network disaggregation saves Rakuten up to 60% on their new 5G network – we've seen the same on fixed broadband networks. Time to goodbye to monolithic network hardware?#networkdisaggregationhttps://t.co/A7YpZPAfqA
— RtBrick (@rtbricknet) August 26, 2020
On this episode of Quick Talk, a TM Forum podcast, we discuss Rakuten Mobile’s #5G deployment delay due to #COVID-19, the impact of US-China relations on @Huawei and taking mobile broadband pricing for granted. Listen now: https://t.co/v26HjWItYF cc: @Rakuten_Mobile
— TM Forum (@tmforumorg) May 28, 2020
Rakuten invests in "AST & Science" space venture to extend future mobile coverage to people and devices across the planet, with the first mobile broadband network that will be broadcast from space.https://t.co/MnD4QDPFlC
— Rakuten Today (@RakutenToday) March 5, 2020
AST & Science raises $110M Series B led by Rakuten and Vodafone to build a broadband network via a constellation of satellites that link directly to smartphones (@chenry_sn / SpaceNews)https://t.co/76BiThEvtohttps://t.co/IQqsJFzkPi
— Techmeme (@Techmeme) March 8, 2020
Rakuten and Vodafone are the lead investors in a just-announced space-based cellular broadband network called SpaceMobile from AST & Science. https://t.co/4eLDMCPcWd
— Via Satellite (@Via_Satellite) March 4, 2020
We are proud to partner with Rakuten to demonstrate #5G's capabilities for enhanced mobile broadband and industry 4.0 applications: https://t.co/AXXCWwLUBV pic.twitter.com/peFzI18vCI
— Nokia for CSPs (@nokianetworks) October 2, 2018
BBWN Bites: Verizon, Spectrum Top Netflix Tier-One Speed Rankings
Also today, Boris's broadband goal gets no love in Parliament, Roku delivers for Apple fans, Tubi targets UK and kids, Rakuten TV brings freebie ad-supported service, Chile seeks tenders forhttps://t.co/ULUbf2u66W— Broadband World Forum (@BBWorldForum) October 15, 2019
Gfast Brings High-Speed Broadband to KDDI MDU Customers
Japanese provider KDDI will use Nokia's Gfast solution to bring speeds of up to 830 Mbit/s to city dwellers.https://t.co/Dw1zkJ7Pbq— Broadband World Forum (@BBWorldForum) February 5, 2019
KDDI and Nokia boost Japanese broadband speeds by 800% https://t.co/DBrYmtCE8e pic.twitter.com/4JZsUnlAXf
— Connected Britain (@ConnBritain) February 4, 2019
For example – here is Masa talking about putting off short-term profits to gain long-term market share. Which he did in the Japanese broadband market in the early 2000s and the Japanese wireless market in the late 2000s.https://t.co/NRanIGHnc9
— Masa Capital (@MasaSonCap) June 9, 2020
Merger delays and teething troubles pull back Sprint and TMO 5G roll-outs…https://t.co/vzN3F8wZZ9#wireless #5G #wifi #cellular #operators #spectrum #RAN #broadband #rethinktechnology @sprint @TMobile @Rakuten @ATT @verizon pic.twitter.com/YswQgCkWcF
— Wireless Watch (@RethinkWireless) September 3, 2019
https://twitter.com/dinoflore/status/1100105372709343234
Nokia and KDDI trial 5G with AirScale radio for wireless ultra-broadband in megacities https://t.co/2CG7axmiFv pic.twitter.com/SrxN7i5DiH
— Nokia News (@nokianews) May 12, 2017
Canada’s telecom watchdog to work with Japan to combat spamhttps://t.co/SUVLncU8zJ pic.twitter.com/vGGfayxUV0
— MobileSyrup (@MobileSyrup) January 6, 2018
.@SoftBank held talks with @BSNLCorporate for leasing out broadband bandwidth from #OneWeb's low earth orbit communication satellites to disrupt the telecom tech landscape in India with low latency Internet and voice services https://t.co/lRPEVPV2eP
— Economic Times (@EconomicTimes) April 27, 2018
SoftBank has agreed to invest around $500 million more in satellite broadband provider OneWebhttps://t.co/T2689aGNIU
— The Wall Street Journal (@WSJ) December 12, 2017
KDDI's broadband deal seeks clout with households https://t.co/OOnmpD8isg pic.twitter.com/DyhYiMtgBI
— Nikkei Asian Review (@NAR) December 8, 2016
Softbank/Sprint CEO Masa Son uses Comcast, and isn't happy with his broadband speeds. #codecon pic.twitter.com/dphPmctFoX
— Brad Molen (@phonewisdom) May 28, 2014
.@SoftBank is unlikely to keep supporting @OneWeb, a source familiar with the situation said, as an activist investor agitates for change at the Japanese internet giant amid rumours that its LEO broadband holding is mulling bankruptcy. https://t.co/CLIYbv9FiY pic.twitter.com/IF1ELWmx9c
— Connectivity Business (@connectivity_b) March 26, 2020
Japan's fussy food shoppers finally go online amid pandemic | The Japan Times. The notable thing here is the comment from a Japanese journalist that Britain is the odd man out with broadband. Even on Japanese islands you get broadband! https://t.co/2pGdBXam0Y
— Maurice is not a nice man (@colonelmuppet) July 5, 2020
Half of UK consumers struggled with broadband speeds — NTT DATA @informationage #data #analytics https://t.co/bOf3GLGplT
— Eric Axelrod (@axelrod_eric) August 29, 2020
Only 8-10% of premises in the UK are connected to full-fibre broadband. It's 97% in Japan.
8 in 10 of us experienced internet problems in the last year.
So we'll make the very fastest full-fibre broadband free to everybody, in every home in our country.
That's real change.
— Jeremy Corbyn (@jeremycorbyn) November 14, 2019
Why do we need action on Broadband? Try this. The UK has low levels of full-fibre broadband internet, at just 7%. In comparison, Portugal has 89%, Japan 97% and South Korea 99%. Now do you see why existing solutions can’t work? If they could have they already would have.
— Richard Murphy (@RichardJMurphy) November 15, 2019
Like Lab has said *so* many times, 95% of people won't have their taxes raised
UK has one of the worst rates of broadband- 7%. Portugal 89%, Japan 97% & S. Korea 99% #freebroadband would boost productivity by £59bill, bring 1/2mill ppl into the work & boost rural economies https://t.co/u5Nwq9rp2O
— antonia jennings (@tweetingantonia) November 15, 2019
Actual Wow!
The BBC describe Labour's plan to hook everyone up to Broadband (like Japan & South Korea do) as Communism
This really is a new level of bias by the BBC – even for their standards. pic.twitter.com/VRCxdCJbx6
— The Pileus #RefugeesWelcome (@thepileus) November 15, 2019
when I was in rural Japan in 2005, I could get 150mbps broadband because the government had built it. In 2019 my parents in rural Suffolk can only get 4mpbs broadband because private enterprise has failed to build it.
— Jonathan Paige (@johnnypaige) November 14, 2019
Average monthly cost of broadband:
Russia: $10
Poland $18
France: $31
Mexico: $33
Germany: $37
Japan: $37
Britain: $40
China: $41
Chile: $46
Denmark: $51
Australia: $53
Sweden: $56
Canada: $58
.
.
.
United States: $68This is why monopolies are bad. https://t.co/3zJ7RDrau9
— Public Citizen (@Public_Citizen) November 11, 2019
Even our internet is neo-Liberal…
Aust is coming last in affordability rankings for entry-level broadband services.
Of developed (OECD) nations, Aust is at 36th. Japan is first, US 6th, UK 7th, New Zealand 21st @QuentinDempster #auspol #nbn https://t.co/yGouPHfeCS
— Denise Shrivell – North Sydney for an Independent (@deniseshrivell) August 27, 2019
Holy shit, New Zealand is ahead of Japan in Speedtest's fixed broadband speed global index https://t.co/2ec6JHO38L pic.twitter.com/YZoFeXuv4E
— Andrew Sykes (@Interlime) September 15, 2018
By the end of 2022, China, Japan, South Korea, Canada and the U.K. will have nearly 2X the amount of mid-band spectrum as the U.S. Our latest report outlines near-term opportunities for the U.S. to close the mid-band spectrum deficit: https://t.co/oiOx1zaXBJ pic.twitter.com/wkk4YR2Qd0
— CTIA (@CTIA) July 11, 2020
Military Cyber Affairs reports Chinese government used China Telecom to divert Internet traffic between 2015 and 2017. The report named 4 specific routes: Canada to South Korea, US to Italy, Scandinavia to Japan, and Italy to Thailand. https://t.co/v0EGoV4YkQ pic.twitter.com/pEMmfAGoGZ
— Laurent Perche (@Laurent_Perche) November 9, 2018
Canada can learn from initiatives in Japan & Australia on broadband use & adoption: https://t.co/5LCZx89zPs #DPSummit17 pic.twitter.com/zUPPjjuGPe
— Canadian Chamber of Commerce (@CdnChamberofCom) February 15, 2017
"5G war" as distraction from universal fiber to the prem #FTTP: "I’ve been hearing about the 5G war for a few years now and I still don’t know what it means…If there is now a 5G war, then why hasn’t there been a fiber-to-the-home war?" https://t.co/uV7MxFSZuh
— U.S. Telecom Infrastructure Crisis (@EldoTelecom) December 27, 2019
After US, Japan, Austalia now its time for Germany to stop Huawei from getting into their critical telecom infrastructure. It is really needed #5G #IoTSecurity https://t.co/Xp4Fx1pB0g
— Contra (@BannaGordhan) November 15, 2018
The British government decided to remove Huawei equipment from its 5G networks by the end of 2027. Two days later, they ask Japan to help build its 5G infrastructures. More on #InsideTelecom.#telecom #tech #5g #Britain #uk #japan #network https://t.co/Gi2yJfJXmo
— InsideTelecom (@insidetelecom_) July 27, 2020
Spot on from @TomTugendhat. “Every general wants to pick the battlefield and divide their enemy…Continuing to allow Huawei into the UK’s networks, triggering the reaction Washington has just ordered, that’s exactly what Beijing is succeeding in doing.” https://t.co/uXLgqs1YOX
— Owen Paterson (@OwenPaterson) May 6, 2020
The US is working with Australia & Japan to stop Chinese telecoms giant Huawei from building a major internet infrastructure project in #PNG. It's the latest sign of international efforts to curb China’s broadening influence in the Pacific
https://t.co/2mGJSQGqaH— Keith Jackson AM (@PNGAttitude) September 28, 2018
The U.S. scrutiny has led governments in Australia, Britain, Canada, Germany, Poland and Japan to all examine their telecom supply chain, as well,while Australia and New Zealand have already restricted Huawei's potential involvement in their coming 5G net https://t.co/aXsGNktiVk
— jasonleeramsey (@jasonleeramsey) January 26, 2019
Ask the Japanese about FTTP #nbn whilst your there, you might learn something about not wasting $20 billion on a copper lemon #auspol #ausbiz #telecom #gennbn #broadband https://t.co/iwZ7O8jic8
— Mark A Gregory (@_markagregory) January 18, 2018
Prime Minister Abe’s Resignation Announcement 安倍首相辞意表明
All the below tweets are in English.
日本時間29日午後2時までに見つけたツイートを取り急ぎ以下貼っておきます。
Shinzo Abe has announced his resignation citing health concerns.
How will his time as Japan's Prime Minister be remembered?
Read more: https://t.co/VK2X9gdljG pic.twitter.com/Yco7hllbPG
— CNN International (@cnni) August 28, 2020
Shinzo Abe has announced his resignation citing health concerns.
How will his time as Japan's Prime Minister be remembered?
Read more: https://t.co/VK2X9gdljG pic.twitter.com/3vdv68HLct
— CNN International (@cnni) August 28, 2020
Japan's longest serving Prime Minister, Shinzo Abe, had bold ideas to build a stronger, more prosperous & confident nation. COVID-19 turned what was to be his banner year into a major disappointment. Abe steps down amid plummeting approval ratings for his pandemic leadership. pic.twitter.com/Iu7Od3WMyZ
— Will Ripley (@willripleyCNN) August 28, 2020
#BREAKING: Japan's Prime Minister Shinzo Abe resigns for health reasons. @willripleyCNN reports pic.twitter.com/H1hJNSHMrB
— CNN Early Start (@EarlyStart) August 28, 2020
Japan's Prime Minister Shinzo Abe holds a news conference https://t.co/r2ACTyT1ku
— Reuters (@Reuters) August 28, 2020
BREAKING: Japanese prime minister Shinzo Abe has resigned due to ill health.
Sky News' @chesh says it's a "big moment" for Japanese politics and it has come as a "shock" announcement during the pandemic.
More on this story here: https://t.co/DZBxRkg0dh pic.twitter.com/KoxE9ZlS5q
— SkyNews (@SkyNews) August 28, 2020
https://twitter.com/QuickTake/status/1299266444786507778
VIDEO: "I have decided to step down from the post of the prime minister!"
Japan's Prime Minister Shinzo Abe announces he will resign over health problems, in a development that kicks off a leadership contest in the world's third-largest economy pic.twitter.com/OLlI85Dzf1— AFP news agency (@AFP) August 28, 2020
PM #Abe steps down citing health reasons pic.twitter.com/LLIoHCIXo2
— Ruptly (@Ruptly) August 28, 2020
BREAKING: Japan's PM Shinzo Abe resigns for health reasons.
Read more: https://t.co/fZ98KQeHXA https://t.co/nOR5NgLBYF
— Al Jazeera News (@AJENews) August 28, 2020
Japanese Prime Minister Shinzo Abe is set to resign, according to national broadcaster NHK.#Japan #Abehttps://t.co/i2GV2XWTtE
— Al Arabiya English (@AlArabiya_Eng) August 28, 2020
Japan's longest serving prime minister Shinzo Abe is resigning due to health reasons. The news revives memories of when he came to West Palm Beach to talk trade with President Trump.
Read more: https://t.co/yA2ru00Phr pic.twitter.com/xGPmVam9Lh— WPEC CBS12 News (@CBS12) August 28, 2020
Wow. The mark of a true leader. Japanese Prime Minister Shinzo Abe resigns after being truthful about the state of his health. pic.twitter.com/jSaHiW1EuF
— Karen Davila (@iamkarendavila) August 28, 2020
#Gravitas | As Japan's Prime Minister, @AbeShinzo invested significant diplomatic capital in developing strong ties with India. @palkisu brings you the story of Abe's relationship with India. pic.twitter.com/x4a5SeP00w
— WION (@WIONews) August 28, 2020
India and Japan relation further strengthened under PM Abe’s leadership.
Wish you a speedy recovery, Sir. https://t.co/7qXzMNmf5q
— Tejasvi Surya (@Tejasvi_Surya) August 28, 2020
Abe to hold phone talks with Trump https://t.co/ML3LNJ7BrT
— NHK WORLD News (@NHKWORLD_News) August 29, 2020
Under an umbrella, Pres Trump descends the steps of Air Force One as lightning strikes in the distance. On the flight back from NH, he told reporters he feels "very badly" about Japanese PM Shinzo Abe stepping down. "I'm just paying my highest respect," he said. pic.twitter.com/MRUfDyeFXj
— Mark Knoller (@markknoller) August 29, 2020
How unusual was Abe’s leadership stability? This @Reuters graphic illustrates it well. pic.twitter.com/UaA9vYEHz7
— Alastair Gale (@AlastairGale) August 28, 2020
Australia is thankful for the true friend we have had in Shinzo Abe as Prime Minister of Japan. His leadership, wisdom, generosity and vision have championed the cause of peace, freedom and prosperity in our region and the world more broadly. pic.twitter.com/GCdRo371ru
— Scott Morrison (@ScottMorrisonMP) August 28, 2020
This is why the world will miss Shinzo Abe https://t.co/ioJlGbSpQD
— Malcolm Turnbull (@TurnbullMalcolm) August 28, 2020
Under Shinzo Abe, Japan spoke with strength and consistency. He hasn’t just been the longest serving Japanese prime minister, he has been one of the very best. The free trade deal epitomised his commitment to liberal values as well as his regard for Australia. pic.twitter.com/3Ds463xuEW
— Tony Abbott (@HonTonyAbbott) August 28, 2020
.@AbeShinzo has achieved great things as PM of Japan – for his country and the world. Under his stewardship the UK-Japan relationship has gone from strength to strength in trade, defence and our cultural links. Thank you for all your years of service and I wish you good health.
— Boris Johnson (@BorisJohnson) August 28, 2020
“@AbeShinzo – your vision, your leadership, and your friendship have brought our two countries closer. For that and for all the years you’ve dedicated to building a better world, thank you. Wishing you good health, my friend.” – Prime Minister Justin Trudeau
— CanadianPM (@CanadianPM) August 28, 2020
Angela Merkel ‘regrets’ Shinzo Abe’s resignation, wishes him best for his health https://t.co/RNSh1U64Gk
— Republic (@republic) August 28, 2020
"We've had a great relationship and I just feel very badly about it," said US President Donald Trump
Read more: https://t.co/vUD3w8CTcd#USPresident #DonaldTrump #Japan #ShinzoAbe #PrimeMinisterAbe #Opoyi
— Opoyi (@Opoyis) August 29, 2020
I am grateful for your friendship and leadership, @AbeShinzo. I’m sad to see you step down, but I know the strong alliance between our countries and peoples will continue for generations to come. Wishing you good health in the years ahead, my friend. pic.twitter.com/M0cMT5y9Dd
— Joe Biden (@JoeBiden) August 28, 2020
It may not be long before the Abe era is mourned by those at home and its allies abroad, Michael Auslin writes.https://t.co/1A76azxpGy
— Foreign Policy (@ForeignPolicy) August 29, 2020
Shinzo Abe may not be popular—but he was successful, William Sposato writes.https://t.co/sdIfOD9kDR
— Foreign Policy (@ForeignPolicy) August 28, 2020
Japanese Prime Minister Shinzo Abe announced he was stepping down on Friday, citing health issues https://t.co/moOKfPbU2i
— TIME (@TIME) August 28, 2020
Japan's Abe Shinzo resigns over ulcerative colitis problems, a condition he has suffered with for decades https://t.co/bNyNjQtUGL
— Newsweek (@Newsweek) August 28, 2020
Shinzo Abe, Japan’s longest-serving Prime Minister, is resigning for the second time—and one year before his term is set to end—due to chronic health issues https://t.co/0ISBK4bdeZ pic.twitter.com/BcTrExMndI
— Forbes (@Forbes) August 28, 2020
Abe is expected to stay on until a new party leader is elected and formally approved by the parliament. https://t.co/8mWy01woM7
— HuffPost (@HuffPost) August 29, 2020
Japanese Prime Minister Shinzo Abe to resign due to deteriorating health https://t.co/XUvxy9D7F8
— CBS News (@CBSNews) August 28, 2020
Shinzo Abe announced plans on Friday to cut short his stint as Japan's prime minister, citing ill health — but the legacy of his economic policies will endure for decades | Analysis https://t.co/K21LECuiyu
— CNN International (@cnni) August 28, 2020
Japanese Prime Minister Shinzo Abe has battled ulcerative colitis for years and two recent hospital visits within a week had fanned questions on whether he could stay in the job until the end of his term as ruling party leader. https://t.co/GGNBfmWV4p pic.twitter.com/hS57uIbU25
— Inquirer (@inquirerdotnet) August 28, 2020
Hudson Institute thanks Prime Minister @AbeShinzo for his longstanding efforts to deepen the Japan-US relationship, and for his personal friendship to Hudson. Under PM Abe’s leadership, Japan achieved great success in those objectives. Our statement: https://t.co/B0CK9vZ5K1 pic.twitter.com/ggcgJwZPMa
— Hudson Institute (@HudsonInstitute) August 28, 2020
"Shinzo Abe’s Decision to Step Down" – Read the Latest Critical Questions Post from the Japan Chair: https://t.co/8iCIGMKplp
— CSIS Japan Chair (@JapanChair) August 28, 2020
PODCAST: What’s next for Japan after Prime Minister Shinzo Abe’s surprise resignation? @solis_msolis discusses on @policypodcasts' The Current. Listen: https://t.co/rvCgJFr0M1
— Brookings FP (@BrookingsFP) August 28, 2020
.@AsiaProgram's @GotoEastAsia and @AbeDenmark react to the news that Japan's Prime Minister Shinzo Abe will resign: https://t.co/dNIf8ym0vF
— The Wilson Center (@TheWilsonCenter) August 29, 2020
Japan PM Abe says he's stepping down because a chronic illness has resurfaced, says, "It is gut wrenching to have to leave my job before accomplishing my goals." https://t.co/inwWiHDn0p
— The Associated Press (@AP) August 28, 2020
BREAKING: Japanese Prime Minister Shinzo Abe will step down as the country’s leader due to chronic health issues, he announced at a press conference Friday. https://t.co/2SzCKPoB8y
— ABC News (@ABC) August 28, 2020
As Prime Minister Shinzo Abe steps down, the score card for his growth policy is marked by gains in driving the world’s third-largest economy, and by missed targets and unresolved challenges https://t.co/0JDhvU98Ej
— The Wall Street Journal (@WSJ) August 28, 2020
Ulcerative colitis, the malady that has forced Prime Minister Shinzo Abe of Japan to resign, is a chronic inflammation of the large intestine that can recur unpredictably, even with treatment. https://t.co/03xB2upq4U
— New York Times World (@nytimesworld) August 28, 2020
Shinzo Abe, Japan’s longest-serving prime minister, announced that he would resign because of ailing health.
Here is a look at his time in office and his legacy. https://t.co/2XSkiKFIoy
— The New York Times (@nytimes) August 28, 2020
PM Abe’s resignation has potentially major consequences for the U.S. Japan is central to our efforts to limit China’s push for power in the Indo-Pacific. Will Abe’s successor remain as stalwart? via @NYTimes https://t.co/KzgEY8et0n
— Nicholas Burns (@RNicholasBurns) August 28, 2020
Japanese Prime Minister Shinzo Abe resigns, citing health reasons https://t.co/OJ3eL63I1O
— The Washington Post (@washingtonpost) August 28, 2020
Shinzo Abe, Japan’s Longest-Serving Prime Minister, Announces His Resignation https://t.co/mmIVhZBgIH
— Daily Caller (@DailyCaller) August 28, 2020
NEW: Japan’s longest-serving prime minister, Shinzo Abe, said Friday he intends to step down because a chronic health problem has resurfaced. He told reporters that it was “gut wrenching” to leave so many of his goals unfinished. https://t.co/vPiYcfeSuW
— Toronto Star (@TorontoStar) August 28, 2020
Japan's Shinzo Abe steps down as PM due to health concerns https://t.co/JW9msLGzhg
— The Vancouver Sun (@VancouverSun) August 28, 2020
Shinzo Abe: Revisionist nationalist or pragmatic realist? https://t.co/nD4xwEXjMu
— BBC News (World) (@BBCWorld) August 28, 2020
Japan's longest-serving prime minister, Shinzo Abe has resigned for health reasons
He was known for his hawkish policies and his signature economic strategy of "Abenomics"https://t.co/dnJoiJhmM0
— BBC News (World) (@BBCWorld) August 28, 2020
Japanese stocks slump and yen rises after Shinzo Abe resignation report – business live https://t.co/ZTFqZi32AD
— The Guardian (@guardian) August 28, 2020
Shinzo Abe resigns as Japanese prime minister due to ill-health – video https://t.co/Ju3eAeXlc2
— The Guardian (@guardian) August 28, 2020
Japan's Prime Minister Shinzo Abe is to resign over health problems, top lawmakers said Friday, in a bombshell development will end a record-setting tenure with no clear successor in yet in place
— The Telegraph (@Telegraph) August 28, 2020
As Shinzo Abe quits, he will be remembered more as a caretaker PM than a radical reformer, writes David McNeill in Nagano (via @irishtimesworld)https://t.co/oEtkjo2F0e
— Irish Times World (@IrishTimesWorld) August 28, 2020
► VIDEO: "I really struggled to make this decision", Japanese PM Shinzo Abe steps down over health issues https://t.co/muandD55fn pic.twitter.com/BMAdyoxdWy
— Irish Times Video (@irishtimesvideo) August 28, 2020
Japanese PM Shinzo Abe to resign amid health concerns – report https://t.co/szeWoqd4Iv pic.twitter.com/Bv2xhLKGPM
— Independent.ie (@Independent_ie) August 28, 2020
Shinzo Abe, Japan’s longest-serving prime minister, says he is resigning because a chronic illness has resurfaced https://t.co/qx8HnPqJQC
— Irish Examiner (@irishexaminer) August 28, 2020
Speculation about his health increased in recent days after he made two separate trips to hospital for unspecified medical checks https://t.co/yQVTcY9gC6
— RTÉ News (@rtenews) August 28, 2020
▶️ Japan: Shinzo Abe quits over health problems https://t.co/Hyr8PbsNvx pic.twitter.com/d1144Rb93f
— FRANCE 24 English (@France24_en) August 28, 2020
Japanese Prime Minister Shinzo Abe is set to resign over health issues.https://t.co/zBzrUSbsnZ
— DW News (@dwnews) August 28, 2020
Without a clear front-runner to succeed him, speculation has persisted that the outgoing Japanese prime minister is eyeing a fourth term.
But Prime Minister Shinzo Abe has now singled out four of his loyal deputies as potential successors.https://t.co/QEkN0k9RgC
— Nikkei Asian Review (@NAR) August 28, 2020
https://twitter.com/Noahpinion/status/1299489049753739265
The yen rallied 1% versus the dollar following Prime Minister Shinzo Abe’s plans to resign due to ill-health https://t.co/fMvD7nwA6F
— Bloomberg (@business) August 28, 2020
https://twitter.com/writerofscratch/status/1299513347960963072